index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
1096,erk,protein,,erk,uniprot,p27361,cytoplasm,go:0005737,mek,protein,,mek,uniprot,q02750,cytoplasm,go:0005737,positive,d,phosphorylation,tyr/thr,vmm18 melanoma cells,melanoma,skin,human,['2464'],nan,nan,"in vmm18 melanoma cells, the dual phosphorylation (tyr/thr) of erk was 9-fold higher in cells grown in 5% serum relative to cells grown in the absence of serum (figure 5, lanes 2 versus 1). there also was an increased level in the dual phosphorylation (ser217/221) of mek (not shown). treatment of vmm18 melanoma cells with a 10 nm dose of bay 43-9006 produced a 75% decrease in the dual phosphorylation of erk (figure 5, lane 4) and reduced the phosphorylation of mek below detection levels (not shown). these results were consistent with the inhibition of b-raf by bay43-9006. on the other hand, when vmm18 melanoma cells were treated with a 10 nm dose of rapamycin, the dual phosphorylation of erk was reduced by about half (figure 5, lane 3). our interpretation of this result is that mtor activity is required to maintain the phosphorylation of erk in melanoma cells. combination treatment of a 10 nm dose of rapamycin plus a 10 nm dose of bay 43-9006 reduced the phosphorylation of erk to a level even below that seen in cells grown in the absence of serum (figure 5, lane 5). this inhibition of erk phosphorylation by combination of rapamycin and bay43-9006 was as effective as inhibition of mek by the u0126 compound (figure 5, compare lanes 5 and 6).",pmc1289294,1,10,20,1,30
1851,mek1,protein,threonine/tyrosine kinase,map2k1,uniprot,q02750,cytoplasm,go:0005737,raf,protein,,raf1,uniprot,p04049,cytoplasm,go:0005737,positive,d,phosphorylation,s217/s221,,,,human,['1273'],nan,nan,"mek1 or mitogen-activated protein kinase kinase 1 is a threonine/tyrosine kinase member of the ras oncogene signaling pathway. ras becomes activated via igf-1r signaling through shc, an alternate intermediate signaling molecule that docks to igf-1rs activation loop via its ptb domain. upon phosphorylation of shc, recruitment of grb2 and sos lead to the activation of ras followed by subsequent activation of raf. it is raf that activates mek1 through phosphorylation of s217/s221. this activation leads to further downstream signaling that regulates cell proliferation, differentiation, and growth 38. our data shows significant increases in phosphorylation when comparing stages i to iv and ii to iii. (fig. 3)",pmc3187934,1,10,20,1,30
2583,pi3k,protein,,,,,,,pten,protein,,,,,,,positive,d,activation,,,myeloma,,,['3633'],nan,nan,"in myeloma, pi3k inhibitors preferentially suppressed pten-null myeloma growth to those expressing pten, indicating that pi3k activation is more critical for growth and survival of those lines with pten mutations than others expressing a functional pten gene [374]. expression of an active akt, reversed wortmannin- and dexamethasone-induced apoptosis and growth inhibition in pten-null myeloma lines, suggesting that akt lies downstream of pi3k for pten-null myeloma survival and dexamethasone resistance [374].",pmc2652403,1,10,19,1,29
2763,pten,protein,,pten,uniprot,p60484,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,inactivation,,,various,,various,['3071'],nan,nan,"in peutz jeghers syndrome, tuberous sclerosis, and other diseases where pten is inactivated, the use of rapamycin as a clinical means to reverse the effect of elevated mtor activity is an attractive option (inoki et al, 2005a). these diseases are distinct from other hamartoma-associated disorders (such as vhl syndrome) since they have an established molecular link to mtor (inoki et al, 2005a). earlier studies demonstrated that pten-inactivated tumour cells exhibit enhanced sensitivity to the rapamycin analog cci-779 (guertin and sabatini, 2005). more recently, several studies have shown that rapamycin treatment, in combination with other chemotherapeutic drugs, can lead to enhanced selective killing of cancer cells. in particular, the protein tyrosine kinase (ptk) inhibitor, imatinib (gleevec, sti571) synergises with rapamycin to inhibit bcr/abl transformed cells (mohi et al, 2004). the effect of rapamycin may be enhanced as a result of imatinib-induced akt/mtor signaling, a complication that is thought to lead to imatinib resistance (burchert et al, 2005). rapamycin can also synergise with paclitaxel, carboplatin, and vinorelbine to induce apoptosis in breast cancer cells (mondesire et al, 2004). cisplatin-induced apoptosis of a549 lung cancer cells is also significantly enhanced when combined with rad001 (beuvink et al, 2005). this could be in part due to reduced translation of p53-activated p21 mrna in a549 and mcf7 cells treated with rad001, thereby allowing the dosage of cisplatin to be reduced (beuvink et al, 2005). also, the use of the egfr/vegfr inhibitor, aee788, in combination with rad001 greatly decreased tumour growth in glioma xenografts (goudar et al, 2005). furthermore, targeting the glycolytic pathway in combination with mtor inhibition may also be useful in cases where dna-damaging agents are less efficient in inhibiting growth and promoting apoptosis of cancer cells (xu et al, 2005).",pmc2361102,1,10,19,1,29
2687,pp2a,protein,serine/threonine protein phosphatase,ppp2r,uniprot,p67775,cytoplasm,go:0005737,s6k1,protein,,,uniprot,p23443,cytoplasm,go:0005737,negative,d,dephosphorylation,,,,,human,['3272'],nan,nan,"pp2a, a serine/threonine (ser/thr) protein phosphatase, is a heterotrimeric holoenzyme composed of a catalytic subunit (pp2ac), an a subunit (also termed pr65), and members of the b subunit families, such as b (pr55), b′ (pr61), b″ (pr72), and b′″ (pr93/pr110) [27]. the phosphatase activity of pp2ac is modulated by its association with pp2a-a, and -b regulatory subunits [27]. of interest, pp2a has been identified as the phosphatase responsible for the dephosphorylation of s6k1 and 4e-bp1, and inhibition of mtor with rapamycin has been shown to stimulate these pp2a-mediated events [28], suggesting that pp2a is a novel downstream target of mtor. it has been suggested that α4 protein, the mammalian homolog of yeast tap42 [29], associates with pp2ac [30]. association of α4 with pp2a, pp4, and pp6 has been linked to rapamycin sensitivity [30]–[32]. in yeast tor phosphorylates tap42 and promotes its association with pph21/22 and sit4 (encoding pp2ac and pp6, respectively), inhibiting their activities [29], [33], although there exists disputation [34], [35]. as in yeast, the consequence of α4 dissociation from pp2a or pp6 in mammalian cells is contradictory. for instance, rapamycin has been reported to inhibit cell proliferation by decreasing pp2a activity through dissociation α4 from the pp2ac [36]. however, other studies [31], [34] do not demonstrate rapamycin-induced dissociation of α4 from pp2a or pp6.",pmc2868031,1,10,19,1,29
2683,pp2a,protein,,,uniprot,p67775,,,chk1,protein,,chek1,uniprot,o14757,nucleus,go:0005634,negative,d,"dephosphorylation, phosphorylation",s344 (human s345),x. laevis egg extracts,,,x. laevis,['1667'],nan,nan,"in human cells, the inhibition of pp2a induced chk1 phosphorylation in the absence of dna damage and also prevented chk1 dephosphorylation after hydroxyurea removal [118]. the knockdown of pp2a increased chk1 phosphorylation on s317 and s345 and in vitro, pp2a was able to directly dephosphorylate chk1 [118]. in x. laevis egg extracts, the addition of pp2a c reversed chk1 phosphorylation at s344 (human s345) after activation by dsb [119]. the inhibition of pp2a also enhanced chk1 phosphorylation following activation by dsb [119].",pmc2954851,1,10,19,1,29
2682,pp2a,protein,,,uniprot,p67775,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,inhibition,,rh1 or rh30,,,human,['3287'],nan,nan,"next, we investigated the role of pp2a in mtor-mediated cell motility. to this end, a monolayer of rh1 or rh30 cells were grown in 6-well plates to 80% confluence, and serum-starved in dmem for 24 h. cell motility was assessed by the wound healing assay, as described previously [23]. following wounding, cells were pretreated with or without oa (100 nm) for 1 h, then treated with or without rapamycin (100 ng/ml) for 2 h, followed by stimulation with or without igf-1 (10 ng/ml) for 22 h. consistent with our previous findings [23], [24], rapamycin inhibited the basal or igf-1-stimulated cell motility by 60–70% in rh1 cells (fig. 3b). igf-1 stimulated the cell motility by ∼3-fold, and this was dramatically attenuated by rapamycin to the basal level (fig. 3b). oa alone did not affect the basal or igf-1 stimulated cell motility significantly, but conferred high resistance to rapamycin inhibition of the basal or igf-1-stimulated cell motility in rh1 cells (fig. 3b). similar results were also observed in rh30 cells (data not shown).",pmc2868031,1,10,19,1,29
3220,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,physical and/or functional interactions,,,,,human,['1389'],nan,nan,"after the discovery of src and egfr, much work has focused on understanding how ptks and their substrates act as a trigger of cellular functions, including malignant cell transformation. these studies include analysis of physical and/or functional interactions, that is, crosstalk, between src and transmembrane receptor/ptks such as platelet-derived growth factor receptor [11], trk/nerve growth factor receptor [12], colony-stimulating factor receptor [13], erbb2/her2/neu [14], and egfr [15,16]. in particular, the interaction of src and egfr has raised much interest because both are ubiquitously expressed and their co-overexpression and/or mutations have often been found in cancer cells of humans and model animals.",pmc3709701,1,10,19,1,29
2647,pik3ca,protein,,pik3ca,uniprot,p42336,,,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,,colorectal cancer cells,,colon,human,['3641'],nan,nan,"to evaluate the consequences of pik3ca alterations, the two most common mutations were inactivated by gene targeting in colorectal cancer cells [405]. biochemical analyses of these cells showed that mutant pik3ca selectively regulated the phosphorylation of akt and of forkhead transcription factors [405]. pik3ca mutations had little effect on growth under standard conditions, but reduced cellular dependence on growth factors [405]. pik3ca mutations resulted in attenuation of apoptosis and facilitated tumor invasion [405]. importantly, treatment with ly294002 abrogated pik3ca signaling and preferentially inhibited growth of pik3ca mutant cells [405]. a recent study also showed that pik3ca mutant colon cancer cell lines have increased metastatic potential in an orthotopic model [406]. two pik3ca mutants observed in breast cancer (e545k and h1047r) were also tested in the mcf-10a immortalized breast epithelial cell line [407]. both variants displayed higher pi3k activity than wild-type p110α yet remained sensitive to pharmacologic pi3k inhibition [407]. in addition, expression of p110α mutants in mammary epithelial cells induced multiple phenotypic alterations characteristic of breast tumor cells, including anchorage-independent proliferation in soft agar, growth factor-independent proliferation, and protection from anoikis [407]. expression of these mutant p110α isoforms also confered increased resistance to paclitaxel and induced abnormal mammary acinar morphogenesis in three-dimensional basement membrane cultures [407].",pmc2652403,1,10,19,1,29
2595,pi3k,protein,,,uniprot,p42336,,,akt,protein,,,uniprot,p31749,,,positive,d,stimulation,,jf32,,,human,['2974'],nan,nan,"we observed reciprocal changes in the erk and akt pathways in response to their respective enzyme inhibitors. in lm2 cells, mek inhibition (by u0126) suppressed early erk1/2 phosphorylation while p-akt levels increased. conversely, pi3k inhibition (by ly294002) increased basal p-erk1/2 levels at the expense of p-akt (4 hrs time point; figure 9c). mek inhibition raised p-erk1/2 and total erk1/2 levels at 24 and 48 hrs, while pi3k inhibition caused a compensatory increase in cellular p-akt levels from 24-48 hrs. jf32 cell growth was also suppressed by each drug; although mek inhibition did not affect p-erk1/2 levels at 4 hrs, p-erk1/2 levels decreased at 48 hrs (figure 9d). pi3k inhibition stimulated erk1/2 phosphorylation from 4-24 hrs, and increased akt phosphorylation throughout the treatment time-course (figure 9g, h).",pmc3135566,1,10,19,1,29
2594,pi3k,protein,,,uniprot,p42336,,,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,,,leukemia cell lines,,human,['3623'],nan,nan,"another study suggested that pi3k has a major role in the control of proliferation and apoptosis of growth factor-independent multiple myeloma cell lines [324]. constitutive activation of this pathway was shown to be a frequent event in the biology of multiple myeloma in vivo and may be more frequently observed in primary plasma cell leukemia [324]. purified plasmocytes from patients with myeloma or leukemia displayed constitutive phosphorylation of akt, fkhrl-1 and p70(s6k), which was inhibited by ly294002 and enhanced by igf-i [324]. another study demonstrated that akt is activated in aml blasts and that p70(s6k) and 4ebp-1, downstream mediators of akt signaling, also are phosphorylated in aml blasts [325]. in a short-term culture system, most aml patient samples showed a dose-dependent decrease in survival after incubation with ly294002 [325]. incubation of aml blasts with rad001 induced only a small decrease in survival of the cells [325]. however, when combined with ara-c, rad001 enhanced the toxicity of ara-c [325]. these results demonstrated that constitutive activation of the pi3k pathway is necessary for the survival of aml blasts and that targeting of this pathway with pharmacologic inhibitors may be of clinical benefit in treatment of aml [325]. another study demonstrated that the overall survival of patients with the akt phosphoryated on ser473 was significantly shorter than that of patients without [326]. thus, the detection of the akt phosphorylation may provide a new tool for identifying aml patients at high risk of an unfavorable outcome [326].",pmc2652403,1,10,19,1,29
2589,pi3k,protein,,,uniprot,,,,raf,protein,,,uniprot,,,,negative,d,inhibition,cd24 expression,rasv12,,,,['1734'],nan,nan,"inhibition of pi3k did not alter the raf-mediated inhibition of cd24 expression. (a–c) rasv12 cells were treated for 16 h with dmso (d), 100 μm ly294002 (ly) and/or 10 or 20 μm sorafenib (s/sor) with ly. (a) western blot analysis was performed as in figure 4. one representative experiment from three replicates is shown. cd24 mrna expression in control and rasv12 was determined by (b) rt-pcr and (c) rt-qpcr as in figure 4. significance was determined by one-way anova with tukey honest significant difference post-hoc analysis, n = 3, a, bp < 0.01. (d) surface cd24 protein was determined by flow cytometry with control and rasv12 for 24 h as above. one representative histogram of isotype (iso) and cd24-stained cells is shown. (e) quantification of cd24 surface protein expression as mean ± s.e.m percentage of cd24+ cells. significance was determined by one-way anova with tukey honest significant difference analysis, n = 3, different lower case letters indicating different groups at p < 0.001.",pmc4525067,1,10,19,1,29
2585,pi3k,protein,,,uniprot,,,,akt,protein,,,uniprot,,,,negative,d,inhibition,,,,"glioblastoma, colon, bladder, prostate, head and neck, cervix, breast cancer, ovarian cancer, nsclc",human,['25'],nan,nan,"over the past decade numerous studies have accumulated supporting the idea that inhibition of pi3k/akt pathway leads to radiosensitization in glioblastoma and various carcinomas, including colon, bladder, prostate, head and neck, and cervix [167–175]. the combination of pi3k inhibitor and radiation causes an increase in apoptosis and a decrease in clonogenic survival, whereas expression of constitutively active akt blocks apoptosis induced by radiation and prevents radiosensitization by pi3k inhibitor, indicating that activated akt promotes cell survival through inhibition of ir-induced apoptosis [167–175]. akt activity also promotes resistance to chemotherapy in breast cancer and ovarian cancer cell lines [176, 177]. when combined with therapies commonly used in breast cancer treatment, the pi3k inhibitor enhances apoptosis caused by doxorubicin, trastuzumab, paclitaxel, etoposide, or tamoxifen, suggesting that inhibition of akt in breast cancer patients may increase the efficacy of these therapies [176, 177]. loss of pten and the presence of active akt are correlated with poor differentiation, lymph node involvement, distant metastasis, and late stage in nsclc patients. preclinical data suggest that modulation of akt activity sensitizes cells to chemo- or radiotherapy [89, 178]. the combinations of drugs that modulate akt activation with the therapeutic modalities used in nsclc are thought to improve cancer treatment [150].",pmc3317191,1,10,19,1,29
201,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,p53mut,protein,mutant,tp53,uniprot,p04637,nucleus,go:0005634,negative,d,inhibition,,t24 and sq20b,,,human,['382'],nan,nan,"the data presented above suggests that inhibition of akt promotes increased turnover of p53mut. inhibiting p53mut function is of particular interest as mutations in p53 are attributed with gain of function phenotypes that accelerate tumor development, promote increased metastasis and resistance to therapy [24, 25]. mutations in p53 mediate resistance to dna damage induced by ionizing radiation (ir) [64] and therefore if our model is correct, akt inhibition should revert this effect. upon treatment with pi-103, the initial high levels of p53mut protein in t24 and sq20b cell lines are reduced concomitantly with decreased phospho-s48-npm and increased sensitivity to ir (fig. s6a and s6b) in line with previous reports [65]. moreover reduction of p53mut independently of akt inhibition, via sirna mediated silencing of p53, increases the sensitivity of t24 cells to ir (fig. s6c). inhibition of akt with mk-2206 mediates reduction in p53mut and clonogenic survival upon exposure to ir (fig. 6a), suggesting that the mechanistic regulation of npm dynamics and arf localization correlates with therapeutic resistance to dna damage. furthermore sirna mediated knockdown of arf expression similarly increased the sensitivity of t24 cells to ir, indicating that arf promotes resistance to ir in p53mut t24 cells (fig. 6b). nucleoplasmic arf is targeted for degradation by the e3-ligase ulf [57], therefore manipulation of ulf levels should have the opposite effect on sensitivity to ir. indeed, depletion of ulf resulted in elevated arf levels and enhanced resistance of t24 cells to ir in an arf dependent manner (fig. s6d). to confirm that phospho-s48-npm is responsible for ir resistance, we next ablated npm expression in t24 cells and expressed sirna resistant npm and npm-s48a mutants. in agreement with our model, overexpression of npm-s48a increases arf nucleolar foci (fig. 6c, bars) and decreases clonogenic survival (fig. 6c). these results suggest that akt mediated phosphorylation of npm-ser48 promotes cellular resistance to ir by promoting arf relocalization to the nucleoplasm and the stabilization of p53mut.",pmc4171619,1,10,19,1,29
2765,pten,protein,,pten,uniprot,p60484,,,akt,protein,,akt1,uniprot,p31749,,,negative,d,binds,,,,,,['1218'],nan,nan,"antibodies against pten, phospho-akt, akt, phospho-erk, erk, phospho-p38, p38, p21/cip1, p27/kip1, cyclin d1, and β-actin were purchased from cell signaling technology, inc. (danvers, ma). enhanced chemiluminescence (ecl) western blot detection reagents were from amersham life sciences inc. (arlington heights, il). terminal deoxynucleotidyl transferase biotin-dutp nick end labeling (tunel) assay kit was purchased from emd biosciences/calbiochem (san diego, ca). sulforaphane was purchased from lkt laboratories, inc. (st. paul, mn). kits for terminal deoxynucleotidyl transferase biotin-dutp nick end labeling (tunel) and caspase-3 assays were purchased from emd biosciences/calbiochem (san diego, ca).",pmc2915986,1,10,19,1,29
2562,pi 3-kinase,protein,,,uniprot,p42336,,,p53,protein,,tp53,uniprot,p04637,,,positive,d,phosphorylation,serine 86,,,,human,['510'],nan,nan,"as expected, inhibition of pi 3-kinase led to rapid dephosphorylation of both akt and gsk3 (figure 6a), corresponding to activation of gsk3. phosphorylation of tip60 on serine 86 increased ∼fourfold following inhibition of pi 3-kinase with either pi-103 or gdc-0941 (figure 6b). likewise, inhibition of pi 3-kinase increased the acetylation of p53 lysine 120 by three-to-four-fold (figure 6c). importantly, both tip60 phosphorylation and p53 acetylation were blocked by treatment with the gsk3 inhibitor sb-21676, demonstrating the functional role of gsk3 in p53 activation. inhibition of pi 3-kinase similarly resulted in gsk3-dependent phosphorylation of tip60 (figure 6d) and acetylation of p53 (figure 6e) in pc12 rat pheochromocytoma cells.",pmc3481126,1,10,19,1,29
2540,phosphatidylinositol 3 kinase (pi3k),protein,,pik3ca,uniprot,p42336,plasma membrane,go:0005886,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,activation,,,,,human,['358'],nan,nan,"the phosphatidylinositol 3 kinase (pi3k)-akt signaling cascade is a vital mediator of essential cellular activities including proliferation and survival [1]. mutations, amplification and deletions of the upstream regulators of akt are among the most frequent somatic events in cancer [2, 3]. consequently, deregulation of akt is a major factor enhancing both oncogenesis and resistance to treatment in many human malignancies [4, 5]. alteration of upstream pathway components, such as activating mutations in ras, pi3k or loss of pten, can be the primary oncogenic event leading to therapeutic failure[2, 6]. however, it is the activation of akt that is proposed to modulate cell death responses to therapeutic agents and mediate resistance [3, 7]. not surprisingly, the aim of regaining sensitivity to various therapies has focused attention on targeting the pi3k-akt pathway [8]. pi3k and akt inhibitors, such as pi-103 and mk-2206 have been investigated as single agents, but their potential as combination agents in specific patient cohorts is anticipated to be where the greatest effectiveness of these agents will be identified [9, 10].",pmc4171619,1,10,19,1,29
202,akt,protein,,,uniprot,p31749,cytoplasm,go:0005737,pi3kca,protein,p110α catalytic subunit,pik3ca,uniprot,p42336,plasma membrane,go:0005886,positive,d,activation,,,cancer cells,various,human,['22'],nan,nan,"akt signaling is frequently activated in human cancers due to genetic and epigenetic alterations and has a role in neoplastic transformation [148–152]. although akt gene mutations are not widely reported, the amplification, overexpression, and activation of akt occurs at high frequency in a number of human cancers [148, 150]. alterations of akt signalling in human cancer also result from mutations of the upstream pi3k kinase and pten. pten is one of the most frequently mutated genes, second only to p53 in human cancers [30, 153]. inactivation of pten is strongly correlated with the activation of akt which in turn controls tumor cell proliferation. pten activity is lost by mutation, deletion, or promoter methylation silencing at high frequency in many primary and metastatic human cancers [154–156]. many activating mutations have also been described in pi3kca gene, upstream of akt, which encodes one of the p110α catalytic subunits of pi3k. pi3kca mutations (e542k, e545k, h1047r) are frequently observed in human colon, gastric, breast, and lung cancers and glioblastoma. they are able to constitutively activate akt and enhance its oncogenic activity [157–162].",pmc3317191,1,10,19,1,29
3221,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,erbb2,protein,,erbb2,uniprot,p04626,plasma membrane,go:0005886,positive,d,phosphorylation,tyrosine residue,"murine fibroblasts, human breast cancer cells",,breast,human,['1401'],nan,nan,"src also participates in cancer cell functions involving the other family member of the egfr and/or its phosphorylation on a tyrosine residue that is analogous to the egfr y845. in murine fibroblasts, c3h10t1/2, and human breast cancer cells, mda-mb-361, where high levels of expression of erbb2 (naturally overexpressed) and erbb3 (ectopically or naturally overexpressed) are evident, mutual interaction between erbb2 and erbb3 takes place. such erbb2-erbb3 interaction was shown to be responsible for the erbb3-dependent (i.e., the erbb3 ligand heregulin-dependent) anchorage-independent growth and cell motility in a src-dependent manner [78]. in mba-mb-361 cells, the heregulin-dependent cell functions involve the phosphorylation of erbb2 on y877, a tyrosine residue analogous to egfr y845 [78]. thus, src-dependent phosphorylation of a tyrosine residue that resides in the activation segment is a phenomenon that occurs commonly for at least two egfr family proteins, egfr and erbb2. the incidence of egfr-erbb2 interaction is also implicated as a prognostic parameter for high malignancy and drug resistance of breast cancer cells, and it is also associated with the occurrence of y845 phosphorylation [79].",pmc3709701,1,10,19,1,29
2424,p70s6k,protein,,,uniprot,p23443,cytoplasm,go:0005737,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,positive,d,inhibition,downstream,nsclc,lung cancer,,human,['3030'],nan,nan,"as shown above, the p70s6k inhibitor pf-4708671 significantly inhibited the activation of p70s6k and its key downstream effector s6, in a concentration dependent manner. furthermore, the protein levels of downstream bad; caspase3 and erk, which affecting apoptosis ability of cells, were increased after treatment with pf-4708671. this proved that pf-4708671 might affect the nsclc cell lines’ survival by regulating relevant factors of apoptosis. in addition, nsclc cell proliferation was time and concentration dependently inhibited by pf-4708671, corroborating previous reports [15–17]. thus, we proposed that p70s6k regulation is associated with cell apoptosis. the differences in minimum effective drug concentrations for the nsclc cell lines assessed may be due to their distinct p70s6k levels and growth rates: we found growth inhibition rate of 30 to 40%.",pmc4714881,1,10,19,1,29
2374,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,p16,protein,,cdkn2a,uniprot,p42771,nucleus,go:0005634,positive,d,induce,,,,,human,['1001'],nan,nan,"senescence is deemed a clinically favorable response to chemotherapy because of its stability and its capacity to stimulate tumor clearance by the immune system [9-11]. senescence is characterized by gross changes in gene expression and chromatin, changes in cellular metabolism, and changes in the function of the cell. senescence is typically a response to stress [12]. dna damage, telomere attrition, or aberrant oncogene expression can induce p53, p16 and/or arf leading to cell cycle exit and senescence [13-16]. however, senescence can also be triggered in a p53 and ink4 independent manner as well. [17-19].",pmc4480747,1,10,19,1,29
2368,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,htert,protein,,tert,uniprot,o14727,nucleus,go:0005634,negative,d,repression,,,,,,['2319'],nan,nan,"we identified multiple potential reciprocal repression (toggle switch) and feedback oscillator motifs as in the examples in figure 7a, which may provide substantial scope for dynamic network behaviour. we also identified several types of coherent feed forward motifs. in particular, three distinct sub-networks form candidate activation and repression “modules”. the activation module links all positive regulators of htert via densely overlapping coherent type 1 motifs, while the repression module comprises several coherent type 2 motifs organised by p53 and ar which inhibit htert and its activators. both motif types are reported to reduce noise in gene expression networks [21].",pmc2714081,1,10,19,1,29
2346,p53,protein,,tp53,uniprot,p04637,,,p21,protein,,cdkn1a,uniprot,p38936,,,positive,d,transcriptional regulation,,h1299,epithelial-like,lung,human,['1040'],nan,nan,"h1299 (p53 null) cells stably integrated with the p21-luciferase reporter were grown in rpmi 1640 medium (invitrogen) supplemented with 10% fetal calf serum and g418. twenty four hours before transfection, the cells were subcultured from confluence to a 1 : 6 dilution into 6-well plates. for transfections for luciferase assays, each well received 0.1 µg of pcmv-renilla (promega), 0.2 µg of pcdna-p53 and various amounts of pcdna-14-3-3 plasmids as indicated in the figure legends. the dna amount was normalized using empty pcdna3.1 vector. transfection was performed with lipofectamine 2000 (invitrogen) according to the manufacturer’s instructions. cells were treated with 0.5 µm cpt or dmso immediately after transfection. twenty four hours after drug treatment, cells were washed twice with pbs and lysed using ripa buffer (150 mm nacl, 1% np-40, 0.5% sodium deoxycholate, 0.1% sds and 50 mm tris–hcl at ph 8.0) to which a complete edta-free protease inhibitor tablet (roche) had been added. luciferase assays were performed with the dual-luciferase reporter assay system (promega) in accordance with the manufacturer’s instructions. wells were prepared in triplicate, and error bars represent 1 sd.",pmc2817464,1,10,19,1,29
2336,p44/42 mapk,protein,,mapk1,uniprot,,cytoplasm,go:0005737,p70 s6 kinase,protein,,rps6kb1,uniprot,p23443,cytoplasm,go:0005737,positive,d,phosphorylation,,h441,epithelial-like,lung,human,['1820'],nan,nan,immunoblot analysis of control and insulin-treated h441 cells using phosphospecific antibodies for p44/42 mapk and p70 s6 kinase revealed that both kinases were in a partially activated state at the 15 min time point. the phosphorylation of the protein kinases in the controls declined over time and remained at minimum levels after 30 min to 2 hours of incubation. we attribute this partial activation of the signaling kinases to the media change that occurred immediately prior to insulin or vehicle addition [21].,pmc150512,1,10,19,1,29
2580,pi3k,protein,kinase,pik3ca,uniprot,p42336,plasma membrane,go:0005886,cyclin d1,protein,cyclin,ccnd1,uniprot,p24385,nucleus,go:0005634,negative,d,blocks,,,,neoplastic,,['2970'],nan,nan,combined mek and pi3k inhibition blocks igf-1 and møcm induced neoplastic proliferation by decreasing cyclin d1 expression,pmc3135566,1,10,19,1,29
2766,pten,protein,,pten,uniprot,p60484,,,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,,,,,humans,['3632'],nan,nan,"loss of pten protein was reported to correlate with pathological markers of poor prognosis in prostate cancer [361]. a relative reciprocity of mutations in pten and nras was also reported in melanoma, suggesting that the two genetic changes, in a subset of cutaneous melanomas, are functionally overlapping [362]. in multiple myeloma (mm) it was shown that human lines possessing the highest akt activity lost pten expression [363]. sequencing analysis demonstrated that the pten gene contained a deletion. restoration of pten expression suppressed igf-i-induced akt activity, suggesting that loss of pten is responsible for uncontrolled akt activity in mm lines [363]. in lymphoma/leukemia-derived cell lines, an inverse relationship between pten and phosphorylated akt was observed in 63% of cell lines [364]. no cell lines showed absence of pten expression, whereas 50% of cell lines showed low pten expression [364]. another study demonstrated the phosphorylation of akt is accompanied by the loss of pten in clinical specimens of endometrial carcinomas [365]. phosphorylation of akt was accompanied by the loss of pten in clinical specimens of endometrial cancers [366]. the survival rate for pten-positive patients was significantly higher than that for pten-negative or -heterogeneous staining patients, and thus pten-positive staining was proposed to be a significant prognostic indicator of favorable survival for patients with advanced endometrial cancer [366]. in glioma, a strong inverse correlation was described between pten levels and both phosphorylated akt expression and akt activity [367]. a significant association was evident between pten expression level and histology. pten levels were highest in normal brain, lowest in gbm tumors, and intermediate in grade ii oligoastrocytomas [367]. another study demonstrated that loss pten was highly correlated with activation of the main pi3k effector akt in vivo [368]. it was also shown that akt activation is significantly correlated with mtor, the family of forkhead transcription factors (foxo1, foxo3a, and foxo4) and the s6 protein [368]. expression of the mutant egfrviii was also tightly correlated with phosphorylation of these effectors, demonstrating an additional route to pi3k pathway activation in glioblastomas in vivo [368]. pten expression correlated significantly with survival time within the entire cohort and was associated with survival within the subgroup of gbm tumors [367]. thus, reduced pten expression is ubiquitous among gbm tumors and may play a role in the development of low-grade gliomas. pten inactivation in gliomas portends a particularly aggressive clinical behavior [367].",pmc2652403,1,10,19,1,29
2285,p21,protein,,cdkn1a,uniprot,p38936,,,cyclin e,protein,,ccne1,uniprot,p24864,,,positive,d,phosphorylation,s130,,,,,['1129'],nan,nan,"the p21 s130 residue can be phosphorylated by cyclin e-cdk2 [61], [62] and also by cdk6 activated by the viral cyclin k [79]. using 2d gel separations, we show that the in vitro phosphorylation of p21 by cyclin e/a-cdk2 occurs mainly at s130 but also at s98 (a residue reported to be phosphorylated by ask1 and jnk1 but not cdks [82]), and we show for the first time that cyclin d-cdk4/6 also readily phosphorylate s130. like p27 in cyclin e-cdk2 complexes [12], p21 is thus both a potential inhibitor and a substrate of cyclin d-cdk4/6 complexes. interestingly, s130 was more efficiently phosphorylated by the different cdk complexes when p21 was bound to cyclin d-cdk4. this, together with two other observations, suggests that p21 is not phosphorylated merely via an autonomous “intra-complex” mechanism. first, binding to inactive cdk4 complexes similarly increased the s130 phosphorylation of p21 in transfected cho cells (figure 4c). second, s130 phosphorylation did not appear after incubation of p21-cyclin d3-cdk4 complexes with high atp concentrations but no other kinase (figure 3b). p21 as a subunit of the cdk4 complex would thus be phosphorylated, and hence regulated, by other active cdk4 and cdk2 complexes. as for cdk2-dependent phosphorylation of p21 on s130 in vitro",pmc3667761,1,10,19,1,29
2769,pten,protein,,pten,uniprot,p60484,,,braf,protein,,braf,uniprot,p15056,,,positive,d,mutation,,,melanoma,skin,mouse,['1969'],nan,nan,"in some cancer settings, pten and braf mutations appear to interact. two studies papers have highlighted the hypothesis of mutant braf- and pten-loss-driven carcinogenesis in mouse models [352,353]. in a study by dhomen et al., inducible expression of b-rafv600e was sufficient to induce multiple melanocytic lesions including skin hyperpigmentation, dysplastic nevi and melanoma [352]. tumor cells from these b-rafv600e mice displayed both melanoma growth and melanocyte senescence in this system. approximately 70% of these mice developed melanomas that exhibited histological and molecular characteristics similar to that of human melanoma and were able to colonize the lungs in nude mice [352]. in contrast, another group of researchers generated mice that conditionally-expressed melanocyte-specific braf v600e that were only able to induce benign melanocytic hyperplasias and were unable to progress any further over a 15-20 month period [353]. however, braf v600e expression in a pten gene-silenced background led to the production of melanomas with 100% establishment, short latency and metastasis to lymph nodes and lungs. this development was prevented by the treatment of mice with either the mtor inhibitor rapamycin or the mek1/2 inhibitor (pd0325901). moreover, while combination treatment with rapamycin or pd0325901 led to the reduction of established tumors, upon termination of drug treatment the melanomas reappeared most likely due to the presence of drug resistant melanoma-initiating cells in these mice. overall, these two papers further validated the mutated b-raf/mek/erk and the pi3k/akt/mtor pathways, as promising therapeutic targets in melanoma.",pmc3660063,1,10,19,1,29
3189,src,protein,,,uniprot,p12931,plasma membrane,go:0005886,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,phosphorylation,y845,,multiple cell types,,multiple organisms,['1424'],nan,nan,"other cellular functions involving y845 phosphorylation include wound-induced activation of the src/egfr pathway in corneal epithelial cells [170], intestinal cell proliferation and tumorigenesis that can be inactivated by the interaction of farnesoid x receptor with src, leading to the inactivation of src and the decrease in y845 phosphorylation [171], and colon cancer proliferation that is stimulated by src-mediated aryl hydrocarbon receptor and egfr interactions, leading to y845 phosphorylation and erk/mapk activation [172]. in primary normal human bronchial epithelial cells, sialyl lewis x modification of egfr involving y845 phosphorylation contributes to wound-induced epithelial repair [173]. another line of evidence shows that reduction of the expression of protein-tyrosine phosphatase-μ results in an increase in tyrosine phosphorylation of egfr, including that on y845, in response to airway epithelial injury [174]. analysis of keratinocytes as a model system for analyzing cutaneous tissue repair also demonstrates the involvement of egfr phosphorylation including y845 [175]. in this case, egfr is trans-activated by the kinin b(1) receptor system; however, the involvement of src in this event is not known. src-dependent y845 phosphorylation also contributes to erk/mapk activation and proliferation of normal keratinocytes, which involves amphiregulin-mediated autocrine signaling of egfr [176]. an alkylating agent, n-methyl-n′-nitro-n-nitrosoguanidine, has been shown to compete with egf in the binding to egfr, thus inhibiting the signaling pathway regulated by egfr phosphorylation, including the basal level of y845 phosphorylation [177]. the sensitization of egf-induced signaling (e.g., intracellular ca2+ release) in primary cultures of rat adrenal chromaffin cells and pc12 cells by bradykinin-dependent g-protein-coupled signal transduction involves src activation and the y845 phosphorylation of egfr [178]. this study also demonstrated that cholesterol-enriched membrane microdomains serve as a platform for the src-egfr functional interaction, and that y845f mutation results in a failure of signal transduction. in an attempt to elucidate the mechanism of nuclear translocation/localization of egfr in cetuximab-resistant nsclc cells (nci-h226), iida et al. [179] have shown that y1101, but not y845, in egfr is a critical tyrosine residue that is phosphorylated by yes and lyn.",pmc3709701,1,10,19,1,29
3182,src,protein,,,,,cytoplasm,go:0005737,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,phosphorylation,y845,,epithelial,mammary,human,['1413'],nan,nan,"the cytotoxicity of arsenic trioxide in keratinocytes involves nadph oxidase/p67phox-mediated production of ros, which is under the control of src activation and y845 phosphorylation of egfr [133]. ros-induced y845 phosphorylation has also been demonstrated in mammary epithelial cells that are treated with benzo[a]pyrene 3,6-quinone and benzo[a]pyrene 1,6-quinone [134]. survival of hepatocytes in the presence of cadmium also involves a mechanism mediated by nadph oxidase, the activation of which in turn activates src, eventually resulting in egfr y845 phosphorylation [135].",pmc3709701,1,10,19,1,29
3160,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,,casp7,uniprot,p55210,cytoplasm,go:0005737,positive,d,phosphorylation,multiple tyrosine sites,mouse embryonic fibroblasts,fibroblast,embryonic,mouse,['965'],nan,nan,"although the rate of development of drug resistance remains very high, 5-fluorouracil (5-fu) is still the most common chemotherapeutic drug used for the treatment of colon cancer. a better understanding of the mechanism of why cancers develop resistance to 5-fu could improve its therapeutic effect. sometimes, antioxidants are used simultaneously with 5-fu treatment. however, a recent clinical trial showed no advantage or even a harmful effect of combining antioxidants with 5-fu compared with administration of 5-fu alone. the mechanism explaining this phenomenon is still poorly understood. in this study, we show that 5-fu can induce reactive oxygen species-dependent src activation in colon cancer cells. mouse embryonic fibroblasts that are deficient in src showed a clear resistance to 5-fu, and knocking down src protein expression in colon cancer cells also decreased 5-fu-induced apoptosis. we found that src could interact with and phosphorylate caspase-7 at multiple tyrosine sites. functionally, the tyrosine phosphorylation of caspase-7 increases its activity, thereby enhancing cellular apoptosis. when using 5-fu and antioxidants together, src activation was blocked, resulting in decreased 5-fu-induced apoptosis. our results provide a novel explanation as to why 5-fu is not effective in combination with some antioxidants in colon cancer patients, which is important for clinical chemotherapy.",pmc4040661,1,10,19,1,29
3159,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,enzyme,casp7,uniprot,p55210,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,human,['982'],nan,nan,"purified wt-caspase-7, mut-caspase-7, wt-caspase-3 and caspase-7 peptides were incubated with active src (upstate biotechnology, inc., boston, ma, usa) and 1 mci of [γ-32p] atp, 100 μm unlabeled atp and kinase buffer (50 mm tris-hcl ph 7.5, 10 mm mgcl2, 1 mm edta, 1 mm dtt and 0.01% brij 35; cell signaling technology, inc.). each reaction was incubated in a 32 °c water bath for 40 min and the reaction was stopped by adding 6 × sds loading buffer. the proteins were resolved by sds-page, and visualized by autoradiography.",pmc4040661,1,10,19,1,29
3158,src,protein,kinase,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,effector,casp7,uniprot,p55210,cytoplasm,go:0005737,positive,d,phosphorylation,,in vitro,,,human,['975'],nan,nan,"to determine whether caspase-7 activity can be influenced by src phosphorylation, an in vitro kinase assay was performed using src and wt-caspase-7 or mut-caspase-7. caspase-7 activity was detected at different time points. caspase-9 is known to be the upstream activator of effector caspases in the intrinsic apoptosis pathway. the presence of caspase-9 protein activated caspase-7 to a higher level than in its absence. our results showed that wt-caspase-7 was first phosphorylated by src, and then adding caspase-9 dramatically increased caspase-7 activity (figure 6a, left panel, supplementary figure 2). in contrast, mut-caspase-7 activity was relatively unaffected in the presence of src and caspase-9 treatment (figure 6a, right panel). 293t cells transfected with wt-myc-caspase-7 exhibited increased caspase-7 activity, whereas little change in caspase-7 activity was observed in cells transfected with mut-myc-caspase-7 (figure 6b). cells co-transfected with src and wt-caspase-7 exhibited a 1.5-fold increase in caspase-7 activity compared with wt-caspase-7 alone. in contrast, no change in caspase-7 activity was observed in cells co-transfected with src and mut-caspase-7 compared with cells transfected with only mut-caspase-7 (figure 6c). overall, these results indicated that src might regulate apoptosis by enhancing caspase-7 activity through phosphorylation.",pmc4040661,1,10,19,1,29
3146,sp1,protein,transcription factor,sp1,uniprot,p08047,nucleus,go:0005634,tp53,gene,,tp53,fplx,tp53,nucleus,go:0005634,positive,d,transcriptional regulation,,a2780,epithelial,ovary,human,['2322'],nan,nan,"since sp1 levels were unaffected, we assessed whether its activity might be dynamically affected under prolonged gsk3 inhibition by chip in a2780 after 21 day 2.5 µm bio treatments. recovery of both htert and tp53 promoters were analysed and compared with recovery after 16 h treatments. in contrast with the results after 16 h, immunoreactive sp1 levels at the htert promoter were increased by 3.7-fold after 21 days treatment. furthermore, sp1 epitope at the tp53 promoter was also increased by 1.6-fold at day 21. these data confirm that sp1 is also dynamically regulated and participates in ongoing remodelling of both htert and tp53 promoters under persistent gsk3 inhibition.",pmc2714081,1,10,19,1,29
3195,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,,casp7,uniprot,q01546,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,vitro,['973'],nan,nan,src phosphorylates caspase-7 in vitro and interacts with caspase-7 in cells,pmc4040661,1,10,19,1,29
3196,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,negative,d,inactivation,,,cancer cell,colon,human,['967'],nan,nan,"src is known to be overexpressed in more than 80% of colon cancers5 and is closely associated with cancer cell proliferation, survival, angiogenesis, adhesion and metastasis.6, 7, 8 however, the relationship between src and apoptosis is controversial. src has been reported to inhibit apoptosis by activating the phosphatidylinositol 3-kinase/akt pathway, which protects cells against pro-apoptotic stimuli through the phosphorylation and inactivation of death accelerators, such as bad, bax and caspase-9.9, 10, 11 src could downregulate caspase-8 activity either directly12 or through activation of the p38-mitogen-activated protein kinase pathway.13 in addition, src could downregulate pro-apoptotic genes to reduce apoptosis.14, 15 on the other hand, src has also been reported to enhance apoptosis induced by different pro-apoptotic stimuli,16, 17, 18 and this effect is triggered specifically at high src signaling levels.19",pmc4040661,1,10,19,1,29
3199,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,egfr,protein,,egfr,uniprot,p00533,cell membrane,go:0005886,negative,d,inhibition,,,colorectal cancer cells,colorectal cancer,human,['1405'],nan,nan,"lu et al. [103] have reported the mechanism of resistance to the anti-egfr monoclonal antibody cetuximab in colorectal cancer that had been made insensitive to this drug by exposure to subeffective doses of cetuximab over an extended period of time. in this system, the inhibition of src activity and y845 phosphorylation of egfr reverses the drug resistance. an alternative explanation for the cetuximab resistance in breast cancer cells was reported by li et al. [104], who showed that breast tumor kinase (btk)/protein-tyrosine kinase 6 (ptk6), a non-receptor, as well as a non-src family ptk, which was originally identified in human melanocytes, is highly expressed in most human breast cancers and that btk/ptk6 seems to be responsible for the y845 phosphorylation, the retention of which confers the resistance of cancer cells to an anti-egfr drug, cetuximab. this was the first report describing that a non-src family ptk can mediate y845 phosphorylation.",pmc3709701,1,10,19,1,29
3040,s6,protein,active form,rps6,uniprot,p62753,cytoplasm,go:0005737,pten,protein,,pten,uniprot,p60484,nucleus,go:0005634,positive,d,activation,pten,,,,human,['901'],nan,nan,"a major challenge for the development of cancer therapy is the identification of predictive biomarkers of efficacy. there are no known predictive biomarkers for the efficacy or resistance in cancer of mtor inhibitors. activation of pi3k signalling, through akt activation, pten deletion, growth factor stimulation or aberrant growth factor receptor signalling, may indicate potential sensitivity of tumours to mtor inhibition [232]. thus, the differential expression of mtor pathway proteins (pten and active forms of akt and s6) may be possibly predictive markers for tumour response to mtor inhibition, as described in glioblastoma, prostate and breast cancer cell lines [233,234]. nevertheless, these predictors of response have been proposed based only on preclinical data and in specific types of cancer, and have not been clinically validated, with the exception of the loss of pten expression, that was used in clinical trials as a marker to evaluate glioblastoma sensitivity to rapamycin treatment [235]. moreover, there is a considerable variation in the therapeutic benefits detected in patients harbouring tumours predicted to be responders to mtor inhibition, because the genetic context in which the altered phenotype occurs may also be important for the patient response to therapy.",pmc3291999,1,10,19,1,29
2893,ras,protein,,,,,,go:empty,erk,protein,phosphorylated,,,,,go:empty,positive,d,activation,,skov3,epithelial,ovarian,human,['1636'],nan,nan,"(a) western blot analysis using anti-ras, phosphorylated erk or gapdh antibody to determine ras/mek activation in control skov3 and ras transformed skov3 (clone 10 and 15). control skov3 and ras transformed skov3 cells were treated with ifn (0, 12.5, 25, 50 and 100 u/ml), and then challenged with challenged with vsv (moi of 1). infection was evaluated by (b) western blot analysis for vsv-g protein and gapdh at 24 hours infection and by (c) progeny virus assay at 48 hours after infection.",pmc3436881,1,10,19,1,29
2890,ras,protein,,hras,uniprot,p01116,plasma membrane,go:0005886,pten,protein,,pten,uniprot,p60484,nucleus,go:0005634,positive,d,unknown,,,cancer,,human,['1915'],nan,nan,"the concept of a driver mutation is very important in cancer. if the driver mutation can be successfully targeted that may lead to elimination of the cancer. this is a mutation that is statistically enriched in a particular cancer and usually thought to be one of the first events in the malignant transformation of those particular cells to cancer cells [12]. examples of driver mutations in these two pathways include ras, nf1, braf, mek1, pik3ca (pi3k), and pten.",pmc3660063,1,10,19,1,29
2889,ras,protein,,hras,uniprot,p01112,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,d,activation,,,,,,['1923'],nan,nan,activation of the ras/raf/mek/erk and ras/pi3k/pten/akt/mtor pathways by genetic mutations,pmc3660063,1,10,19,1,29
3200,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,phosphorylation,tyr845,hek293 cells,epithelial-like,kidney,human,['2144'],nan,nan,"src is known to be expressed in hek293 cells (abrahamsen et al., 2003; arinsburg et al., 2006). consistent with these studies, we found the expression of src in hek293 cells (fig. 4b). the phosphorylation of tyr416 in the activation loop of src protein is associated with the increased activity (hunter, 1987). when hek 293 cells were transfected with ep2, the levels of endogenous p-src were not significantly altered due to the low transfection efficiency with transient transfection (data not shown). therefore, we co-transfected hek293 cells with ep2 and src expression plasmids and the effect of ep2 on src phosphorylation was examined. because the previous results suggest that src is a potential upstream kinase for ep2-induced p38 phosphorylation, we anticipated that over-expression of ep2 would increase src activity. when hek 293 cells were co-transfected with expression vectors for ep2 and src, p-src (tyr416) levels were increased compared to those in vector and src-transfected cells (fig. 4b), indicating that ep2 overexpression induces the phosphorylation of src. then we examined if ep2 overexpression increases src activity. because tyr845 in egfr is a substrate for src and known to be phosphorylated by src (biscardi et al., 1999; tice et al., 1999), we hypothesized that ep2 would activate src, which in turn results in increase in egfr phosphorylation at tyr845. to test this, hek293 cells were co-transfected with expression vectors for ep2 and egfr and incubated with or without pp2. western blot analysis for phosphorylated tyr845 in egfr (fig. 4b) showed that the phosphorylation was increased by ep2 overexpression compared to vector and egfr-transfected cells. furthermore, ep2-induced increase in tyr845 phosphorylation was blocked by pp2 treatment, indicating that ep2 overexpression increases endogenous src activity. these results demonstrate that ep2 induces the phosphorylation and the activation of src.",pmc4624070,1,10,19,1,29
2788,pten,protein,tumor suppressor,pten,uniprot,p60484,cytoplasm,go:0005737,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,d,phosphorylation,,,glioma,brain,human,['3651'],nan,nan,"further work provided the first evidence that the systemic administration of a pi3k inhibitor ly294002 has antitumor and antiangiogenic activity in vivo [442]. it was shown that pten reconstitution diminished phosphorylation of akt, induced the transactivation of p53 and increased the expression of p53 target genes in glioma cells [442]. pten and ly294002 induced p53 activity in human brain endothelial cells, suggesting that pten and pi3k pathways can suppress the progression of cancer through direct actions on tumor and endothelial cells [442]. ly294002 inhibited glioma tumor growth in vivo, induced tumor regression, decreased the incidence of brain tumors, and blocked the tumor-induced angiogenic response in vivo [442]. these data provided evidence that both pten and pi3k inhibitors regulate p53 function and display in vivo anti-angiogenic and anti-tumor activity [442]. these results provided evidence that the two tumor suppressor genes, pten and p53, act together to block tumor progression in vivo. ly294002 inhibited ascites formation in a mouse model of human ovarian cancer by inhibiting tumor and peritoneal neovascularization as well as vascular permeability [443]. ly294002 also directly inhibited vegf protein expression and release from ovarian carcinoma, suggesting that the inhibitor blocks the vegf signaling pathway involved in angiogenesis and vascular permeability [443].",pmc2652403,1,10,19,1,29
2786,pten,protein,phosphatase,pten,uniprot,p60484,nucleus,go:0005634,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,d,phosphorylation,,pancreatic cancer cell lines,,,human,['1195'],nan,nan,"pten (phosphatase and tensin homolog deleted on chromosome 10, also called mmac1 or tep1) is a tumor suppressor gene [28-30], which is frequently deleted or mutated in a wide range of human cancers, including glioblastoma [31], melanoma [32], and prostate [33], breast [34], and endometrial cancers [35]. while point mutations in pten rarely occur in pancreatic cancer [36,37], functional inactivation of pten through promoter methylation [38], loss of protein expression [39], reduction of mrna levels [40], or loss of heterozygocity (loh) of linked markers [37,41] occur with high frequency. phosphatidylinositol 3,4,5-trisphosphate (pip3) is a substrate of pten [42-44]. akt is a serine-threonine protein kinase regulated by pip3 that is implicated in survival signaling in a wide a variety of cells, including fibroblastic, epithelial, and neuronal cells [45]. pten increases sensitivity to cell death in response to several apoptotic stimuli by negatively regulating the pi3k/akt pathway [43]. in addition to its role in regulating the pi3k/akt cell survival pathway, pten also inhibits growth factor-induced shc phosphorylation and suppresses the map kinase signaling pathway [46], suggesting that pten has roles in independent of pi3k/akt signaling pathway. hyperactivation of akt is associated with resistance to apoptosis, increased cell growth, cell proliferation, metastasis, angiogenesis, and cellular energy metabolism [45,47-54]. overexpression of akt has been reported in a variety of human cancers, including pancreatic cancer, and cells expressing elevated levels of akt are less sensitive to apoptosis stimuli [38,55-57]. antagonizing pi3k activity negatively regulates akt activity. once activated, however, akt exerts antiapoptotic effects through phosphorylation of substrates such as bad [58,59] and caspase-9 [60] that directly regulate the apoptotic machinery, or human telomerase reverse transcriptase subunit [61], forkhead transcription family members [62,63] and ib kinases [64] that indirectly inhibit apoptosis [65]. studies in pancreatic cancer cell lines have demonstrated that pi3k is required for growth and survival of tumor cells [66-68]. furthermore, amplification or activation of akt2 occurs in up to 60% of pancreatic cancer [39,69-71], supporting the participation of an activated pi3k-akt axis in this disease.",pmc2915986,1,10,19,1,29
2779,pten,protein,negative regulator,pten,uniprot,p60484,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,induction,,"mouse embryonic fibroblasts, mouse prostate epithelium, mouse hematopoietic stem cells, human endothelial cells, mouse primary keratinocytes",,,"mouse, human",['3341'],nan,nan,"multiple lines of evidence indicate that increased pi3k/akt signalling also induces cell senescence. loss of pten, the major negative regulator of the pi3k/akt pathway, induces senescence in mouse embryonic fibroblasts (chen et al., 2005) and mouse prostate epithelium (chen et al., 2005; alimonti et al., 2010a). pten deletion also induces loss of mouse hematopoietic stem cells by induction of the senescence effectors p53, p21 and p19arf (yilmaz et al., 2006; zhang et al., 2006). expression of constitutively active akt induces senescence in human endothelial cells (miyauchi et al., 2004), mouse embryonic fibroblasts (chen et al., 2005; mavrakis et al., 2008; nogueira et al., 2008) and mouse primary keratinocytes (moral et al., 2009). the mechanisms underlying induction of senescence by akt are poorly defined, although the accumulation of reactive oxygen species has been implicated as playing a role (nogueira et al., 2008). a better understanding of the mechanisms of pi3k/akt-induced senescence will be crucial for understanding the role of dysregulated pi3k/akt signalling in cancer.",pmc3325598,1,10,19,1,29
3208,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,noxa1,protein,,nox1,uniprot,q9y5s8,cytoplasm,go:0005737,positive,d,phosphorylation,tyr110,hek293,epithelial,kidney,human,['1363'],nan,nan,"src phosphorylates noxa1 on tyr110. (a and b) noxa1 is targeted by src-mediated phosphorylation. one representative experiment from three separate experiments is shown. (a) hek293 cells were transfected with flag-tagged noxa1 along with srcyf or srckm as indicated. after 24 h, cells were lysed and cell extract were resolved by sds-page using noxa1-specific antibody. (b) hek293 cells were transfected as indicated and cell extracts were treated or not with calf intestinal phosphatases (cip) as described in material and methods. proteins were resolved by sds-page and the presence of a phosphorylation doublet corresponding to noxa1 was detected using noxa1-specific antibody. (c) endogenous and ectopically-expressed noxa1 is tyr-phosphorylated by src in ht29 cells. ht29 cells were transfected with empty vector or with noxa1 expression vector and treated as indicated with pp2 or pp3. after 24 h, cells were lysed and ip was performed using noxa1-specific antibody. the levels of endogenous or ectopically-expressed noxa1, which was tyr-phosphorylated, were analyzed using anti-p-tyr antibody (lower panel), while the presence of noxa1 in cell lysates was verified by reblotting the membrane with noxa1-specific antibody (upper section). one representative experiment from three separate experiments is shown. (d) a schematic representation of the predicted phosphorylation sites on human noxa1 protein (accession number nm_006647) using bioinformatics tools available online (www.cbs.dtu.dk). the phosphorylation potential represents the likeness of a residue to be phosphorylated. its value is included between 0 (low phosphorylation potential) and 1 (high phosphorylation potential). phosphorylation potential (y axis) is plotted for each amino acid residue of noxa1 (x axis). the blue and the green lines indicate serine (ser) and threonine (thr) residues which could be targeted by ser/thr kinases. the red lines indicate tyrosine (tyr) residue which can be phosphoryalted by tyr-kinase. the black arrow indicates the tyr110 of noxa1 as the residue with the highest phosphorylation potential for tyr-kinase (=0.87). (e) src phosphorylates noxa1 on tyr110. hek293 cells were transfected as indicated with srcyf and with myc-tagged wild type noxa1, unphosphorylable noxa1 y110a and phosphomimetic noxa1 y110e. after 24 h, cells were lysed and ip was performed using noxa1-specific antibody. the levels of tyr-phosphorylated noxa1 were analyzed using anti-p-tyr antibody (lower panel), while comparable expression levels of transfected myc-tagged noxa1 mutants was verified by reblotting the membrane with myc antibody (upper section). one representative experiment from three separate experiments is shown. (f) src phosphorylates noxa1 directly. noxa1 wt and noxa1 y110a were transfected in hek293 cells and immunoprecipitated using noxa1 specific antibody. an in vitro kinase assay was performed using recombinant active src as in materials and methods. the levels of tyr-phosphorylated noxa1 were analyzed using anti-p-tyr antibody (upper panel), while immunoprecipitation efficiency was verified by reblotting the membrane with myc antibody (lower section).",pmc2993755,1,10,19,1,29
2775,pten,protein,,pten,uniprot,p60484,nucleus,go:0005634,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,negative,d,downregulation,promoter,,hepatocyte,liver,"mouse, human",['1966'],nan,nan,"alterations in pten expression have also been implicated in hcc. the best evidence that strongly supports the connection between pten-suppression and liver carcinogenesis comes from genetic studies. all mice with pten-deficient hepatocytes exhibited liver adenomas and 66% of them developed hcc [334]. in these mice, hepatocytes were hyperproliferative and displayed an abnormal activation of akt [334]. furthermore, although mutations in the pten gene rarely occur in hcc, frequent loss of heterozygosity of pten allele has been identified in 20-30% of hcc patients [335-338]. in addition, down-regulation of pten expression may be partly due to pten promoter methylation [339]. pten expression plays a critical role in hcc progression and patient's outcome. patients with high expression of pten had a significantly better overall survival than patients with low pten expression [340]. hepatitis viruses protect hepatocytes from apoptotic cell death by promoting the activation of ras/pi3k/akt/mtor survival pathway [341,342]. among the four proteins encoded by hbv genome, hbx has been reported to be involved in hepatocarcinogenesis. it has been reported that hbx expression downregulated pten expression in hepatocytes [342]. in contrast, pten expression in liver cells downregulated hbx-induced pi3k and akt activities [343]. therefore, these studies suggest the possible use of pten as a target in therapeutic approaches for the treatment of at least those hcc caused by hbv infection.",pmc3660063,1,10,19,1,29
3219,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,egfr,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,positive,d,phosphorylation,y845,,normal and cancerous,normal,human,['1428'],nan,nan,"for the past eighteen years or so, since the initial discovery of the src phosphorylation of egfr on y845, much progress has been made in the recognition that y845 phosphorylation takes place in a variety of cancerous and normal physiological cell contexts, as well as in the understanding that y845 phosphorylation plays pivotal roles in these cellular contexts (figure 2). because egfr and src are expressed in almost all normal cells and tissues, the possible impact of their molecular interactions that lead to y845 phosphorylation may not be limited to the known phenomena described in this review article, but rather spread more to other cellular functions that have not yet been documented. egfr and src are prototypical gene products, whose viral counterparts are oncogenic, and molecular and enzymatic functions are the transmembrane receptor ptk and the cytoplasmic non-receptor ptk, respectively. the co-overexpression of these proteins sometimes confers high malignancy for certain kinds of human cancer, and their continued study should provide more information of fundamental importance in the field of basic cell biology, as well as in cancer and other pathological areas of cell biology and medicine.",pmc3709701,1,10,19,1,29
2772,pten,protein,,pten,uniprot,p60484,,,pi3k,protein,,,,,,,negative,d,down-regulating signaling,,breast cancer cells,,,,['3631'],nan,nan,"pten was shown to suppress breast cancer growth through down-regulating pi3k signaling, which leads to the blockage of cell cycle progression and the induction of cell death in a sequential manner [354]. in breast cancer cells under anchorage-independent conditions, pten also induced anoikis, a form of apoptosis that occurs when cells are dissociated from the extracellular matrix, which is enhanced in conjunction with low serum culture conditions [355]. together, these data suggest that pten effects on the pi3k signaling cascade are influenced by the cell stimulatory context, and that depending on the exposure to growth factors and other exogenous stimuli such as integrin ligation, pten can induce cell cycle arrest, apoptosis or anoikis in breast cancer cells. the tumour suppressor activities of pten were linked to the machinery controlling cell cycle through the modulation of signaling molecules whose final target is the functional inactivation of the retinoblastoma gene product [356]. expression of wild-type pten reduced the expression of cyclin d1 [357]. cyclin d1 reduction was accompanied by a marked decrease in endogenous retinoblastoma (rb) protein phosphorylation on cyclin d/cdk4-specific sites, showing an early negative effect of pten on rb inactivation. pten expression also prevented cyclin d1 from localizing to the nucleus during the g(1)- to s-phase cell cycle transition [357]. the pten-induced localization defect and the cell growth arrest could be rescued by the expression of a nucleus-persistent mutant form of cyclin d1, indicating that an important effect of pten is at the level of nuclear availability of cyclin d1 [357]. furthermore, in human glioblastoma cells, pten mutation can cooperate with egfr activation to increase vegf mrna levels by transcriptionally up-regulating the proximal vegf promoter via the pi3k/akt pathway [358]. in addition, the ability of pten to potently inhibit h-ras-induced morphological transformation and anchorage-independent growth in nih3t3 cells was reported [359]. it was also shown that pten can regulate prostate cancer cell proliferation and apoptosis through inhibition of igf-ir synthesis [360].",pmc2652403,1,10,19,1,29
3222,src,protein,,src,uniprot,p12931,plasma membrane,go:0005886,erk1/2,protein,,,uniprot,p27361,cytoplasm,go:0005737,positive,d,phosphorylation,,,,,human,['2063'],nan,nan,"cell lysates were collected and analyzed for a) py418 src and total cellular src (c-src), b) phospho-erk1/2 and total erk1/2 c) phospho- akt and total akt. representative western blots are shown and quantitative data are mean± sem of at least three independent experiments. * p<0.05, compared with 0nm control, #, p<0.05, compared with different cell line. d) five hundred μg of total cell lysate was immunoprecipitated with 10μg of anti-src antibody and analyzed for co-precipitated na/k atpase α1. a representative western blot is shown. values are mean ± sem from at least three independent experiments. * p<0.05 compared with control.",pmc4638348,1,10,19,1,29
2275,p110δ,protein,isoform,pik3cd,uniprot,o00329,endothelial cells,go:0072562,akt,protein,,akt1,uniprot,p31749,,,positive,d,phosphorylation,,,endothelial,,human,['3657'],nan,nan,"the p110δ isoform was shown to be expressed in endothelial cells [461]. the p110δ specific inhibitor ic486068 abrogated radiation-induced phosphorylation of akt. ic486068 enhanced radiation-induced apoptosis in endothelial cells and reduced cell migration and tubule formation of endothelial cells in matrigel following irradiation [461]. ic486068 enhanced radiation-induced endothelial cytotoxicity, resulting in tumor vascular destruction and tumor control when combined radiotherapy in murine tumor models [461]. these findings suggest that p110δ is a therapeutic target to enhance radiation-induced tumor control [461].",pmc2652403,1,10,19,1,29
3194,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,,casp7,uniprot,p55210,cytoplasm,go:0005737,positive,d,co-localization,,sw480,colorectal,,human,['983'],nan,nan,"sw480 cells (1 × 105) were seeded in a four-chamber polystyrene vessel tissue culture glass slide (bd biosciences) and were treated or not treated with 50 μm 5-fu for 48 h in a 37 °c incubator. cells were fixed with 4% formalin for 15 min at room temperature in the dark. after gentle washing twice for 10 min each with pbs, cells were blocked with pbs, 0.02% tween-20 and 1% bsa in a 37 °c incubator for 1 h. cells were then incubated with a 1 : 100 dilution of a src rabbit antibody and a 1 : 50 dilution of a caspase-7 mouse antibody in pbs and 3% bsa by gently rocking at 4 °c overnight. after washing twice for 5 min each, cells were incubated with a 1 : 200 dilution of alexa fluor 488 goat anti-rabbit antibody and alexa fluor 568 goat anti-mouse antibody (invitrogen) for 1 h in the dark. co-localization of proteins was observed by laser scanning confocal microscopy (nikon c1s1 confocal spectral imaging system, nikon instruments co., melville, ny, usa) using a cfi plan fluor × 40 oil objective and then analyzed using the ez-c1 (v3.20) software program (nikon).",pmc4040661,1,10,19,1,29
3400,tsc2,protein,,tsc2,uniprot,p49815,,,erk,protein,,mapk1,uniprot,p28482,,,positive,d,phosphorylation,,,,,,['2013'],nan,nan,"akt also phosphorylates the proline-rich akt substrate of 40 kda (pras40), another inhibitor of mtorc1. when pras40 is phosphorylated by akt, it can not suppress mtorc1 signalling [154,154,165,169,183-185]. thus, this is another mechanism by which akt activates mtorc1. to complicate matters, pras40 is a substrate of mtorc1 itself, and mtorc1-mediated phosphorylation of pras40 prevents inhibition of additional mtorc1 signaling. the ras/raf/mek/erk signaling pathway also regulates mtorc1. tsc2 is phosphorylated by both erk and p90rsk-1. when tsc2 is phosphorylated by either erk or p90rsk-1, its inhibitory function is suppressed [183-185]. moreover, inhibition of mtorc1 can result in erk1/2 activation, through p70s6k/pi3k/ras/raf/mek [186].",pmc4102778,1,10,19,1,29
1083,erk,protein,docking domain,,uniprot,p27361,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,negative,d,inhibition,docking domain,,,,,['277'],nan,nan,characterization of erk docking domain inhibitors that induce apoptosis by targeting rsk-1 and caspase-9,pmc3025971,1,10,19,1,29
1000,egfr,protein,,,uniprot,p00533,cell membrane,go:0005886,irs,protein,,,uniprot,p35568,cytoplasm,go:0005737,negative,d,phosphorylation,,hek293,,,human,['2679'],nan,nan,"the model also incorporates and analyzes complex feedback circuitry of the egfr and ir networks. for instance, pip3-dependent positive feedback circuits in the model involve gab1–pi3k and irs–pi3k interactions (rodrigues et al, 2000; johnston et al, 2003; mattoon et al, 2004). activated erk inhibits sos (dong et al, 1996; fucini et al, 1999), gab1 (lehr et al, 2004) and irs (de fea and roth, 1997) by direct phosphorylation. activated mtor mediates multiple modes of feedback, including positive feedback to akt and negative feedback loops to irs (gual et al, 2003; sarbassov et al, 2005). although akt-induced inhibitory phosphorylation of raf (zimmermann and moelling, 1999; wellbrock et al, 2004) is included in the model, we assume this inhibition to be weak in hek293 cells, as no noticeable mek or erk activation was detected experimentally, following inhibition of akt activity (see supplementary figure s4). the current model involves many parameters that have no analogs in our previously published models. we used the experimental data that are shown in figures 2 and 3 (excluding experiments with pi3k inhibitor) as a training data set to obtain reasonable fit between the model simulations and data by manually varying the parameter values (see supplementary table s1). however, when parameters were fitted, their upper and lower bounds were in agreement with experimental observations for similar reaction types. in addition, reaction rates were always constrained not to be faster than the diffusion limit.",pmc2683723,1,10,19,1,29
960,egf,protein,,,uniprot,p01133,extracellular region,go:0005615,erk1/2,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,,mdck,epithelial,kidney,human,['1776'],nan,nan,"egf-induced erk1/2 phosphorylation and p-erk1/2–dependent inhibition of ina in mdck cell lines. g525c, r564st, p616, and t613a mdck cell lines were grown to confluence on filters and bathed in im for 48 h. (a) individual monolayers were treated with vehicle (lane c; dmso, 10 μl, both sides, 45 min), egf (lane e; egf, 20 ng/ml, basolateral, 15 min), erk kinase inhibitor (u; u0126, 10 μm, both side, 45 min), or erk kinase inhibitor plus egf (u + e; u0126, 10 μm, both side, 30 then egf, 20 ng/ml, basolateral, 15 min). cells were then lysed, separated by sds-page, and probed for phosphorylated erk1/2 and total erk1/2. the blots are representative of three independent experiments. densitometry was performed on each blot and the ratio of perk1/2 to total erk1/2 was determined for each cell line under each condition and the data are summarized in b. (c) confluent monolayers of g525c, r564st, p616l, and t613a mdck cell lines were exposed to egf (20 ng/ml, 30 min, basolateral) with or without pretreatment with an erk kinase inhibitor (u0126; 10 μm, 15 min, bilateral). the inhibition of ina was calculated as previously described. n = 5. p < 0.05. *, significantly different compared with g525c control; **, significantly different compared with monolayers not treated with u0126.",pmc2151644,1,10,19,1,29
950,egf,protein,,egfr,uniprot,p00533,plasma membrane,go:0005886,akt,protein,kinase,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,activation,,,,,human,['2677'],nan,nan,"we have developed a computational model to describe in quantitative terms how cell stimulation by egf and insulin is linked to the activation of ras/erk and pi3k/akt pathways. the current model stems from our previously developed egfr network models that were based on in vitro and in vivo measurements of signaling kinetics. a number of egfr signaling model predictions were validated in our own studies (kholodenko et al, 1999; moehren et al, 2002; kiyatkin et al, 2006; birtwistle et al, 2007) and, in addition, tested by other groups (schoeberl et al, 2002; hatakeyama et al, 2003; resat et al, 2003; blinov et al, 2006). this paper extends our previous models to incorporate ir signaling and regulatory processes involved in egfr–ir crosstalk. however, we do not create a combinatorially complex in silico replica of all distinct biochemical species and interactions, which would be impractical (borisov et al, 2005; hlavacek et al, 2006; birtwistle et al, 2007). instead, we construct a basic, minimal model of the combined egfr and ir networks. the goal of this model is to provide an insight into the mechanisms of cellular responses to combined egf and insulin treatment that can account for our data.",pmc2683723,1,10,19,1,29
941,egf,protein,,egf,uniprot,p01133,cell membrane,go:0016020,erk,protein,,erk,uniprot,p27361,cytoplasm,go:0005737,positive,d,sustained signaling,erk signaling pathway,,,,human,['2693'],nan,nan,"our results suggest that co-stimulation with low, physiological egf doses and insulin endows the mitogenic egfr pathway with more sustained erk signaling. early observations showed that the duration of erk activation is crucial for cell fate decisions (marshall, 1995). in these classical experiments, pc12 cells proliferated after transient erk activation by egf, but differentiated after more sustained erk activation by the nerve growth factor. subsequent work revealed that the duration of erk activation is sensed by a network of immediate early genes, including the transcription factor c-fos (murphy et al, 2002), while the differential timing of erk signaling is explained by subtle alterations in signaling circuits, induced by distinct ligands (kholodenko, 2007).",pmc2683723,1,10,19,1,29
3230,src,protein,tyrosine kinase,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,cysteine protease,casp7,uniprot,q14790,cytoplasm,go:0005737,positive,d,phosphorylation,"tyr58, tyr151, tyr229, tyr230",,,,human,['974'],nan,nan,"after confirming that src can phosphorylate caspase-7, the next step was to identify the site(s) of caspase-7 that can be phosphorylated by src. the potential tyrosine phosphorylation sites were predicted by the netphos 2.0 software program as previously described27 (figure 5a). nine peptides were designed and synthesized commercially (peptide 2.0, houston, tx, usa). the peptide array results indicated that tyr58, tyr151, tyr229 and tyr230 of caspase-7 are likely to be the most important sites to be phosphorylated by src (figure 5b). when all four sites were mutated to phenylalanine, the in vitro kinase assay results showed that phosphorylation of the mut-caspase-7 protein by src decreased dramatically compared with wt-caspase-7, suggesting that these four sites, tyr58, tyr151, tyr229 and tyr230, are the most important sites of caspase-7 to be phosphorylated by src (figure 5c).",pmc4040661,1,10,19,1,29
827,craf,protein,,craf,uniprot,p04049,,,akt,protein,,akt,uniprot,p31749,,,positive,d,phosphorylation,,,b-cell,,human,['2973'],nan,nan,"møcm induced early increases in craf, akt and gsk-3β phosphorylation, and erk1/2 phosphorylation peaked at 24 hrs (figure 9c, d). in both lm2 and jf32 cells, increased akt phosphorylation corresponded to more phosphorylation of the akt substrate, pgsk-3β (figure 9h and 9i). phospho-craf levels, another marker of akt activity, also increased in concert with heightened increased akt activity from 4-24 hrs; although p-craf abruptly dropped at 48 hrs, pakt and pgsk-3β levels remained highly elevated (figure 9f, h and 9i).",pmc3135566,1,10,19,1,29
818,class i pi3k,protein,,,uniprot,p42336,plasma membrane,go:0005886,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,control,,,,,,['3611'],nan,nan,"autophagy is a vacuolar, self-digesting mechanism responsible for the removal of long-lived proteins and damaged organelles by the lysosome [270, 271]. the discovery of the autophagy (atg) genes has provided key information about the formation of the autophagosome, and about the role of macroautophagy in allowing cells to survive during nutrient depletion and/or in the absence of growth factors [270, 271]. two connected signaling pathways encompassing class i pi3k and mtor play a central role in controlling macroautophagy in response to starvation [271]. however, a considerable body of literature reports that macroautophagy is also a cell death mechanism that can occur either in the absence of detectable signs of apoptosis (via autophagic cell death) or concomitantly with apoptosis [271]. macroautophagy is activated by signaling pathways that also control apoptosis [271].",pmc2652403,1,10,19,1,29
3390,tsc2,protein,,tsc2,lrg_486,,,,irs-1,protein,,irs1,,,,,positive,d,maintains expression,,,mefs,,,['680'],nan,nan,"−/− mefs (fig. 2 b). importantly, this reduction is fully reversed by stable retroviral introduction of wild-type tsc2 (fig. 2 b). interestingly, the level of irs-2 mrna is unaffected by the absence of functional tsc2. a similar result is obtained comparing the levels of irs-1 protein in these cells by western blotting, whereas the levels of irs-2 protein or of the insulin or igf receptors is unaffected by tsc2 expression (fig. 2 c). thus, irs-1 expression is maintained by the presence of functional tsc2.",pmc2172316,1,10,19,1,29
3407,tsc2,protein,,tsc2,uniprot,p49815,,,p70s6k,protein,,rps6kb1,uniprot,p23443,,,negative,d,phosphorylation,,,tumor cells,,human,['2270'],nan,nan,"we next examined if upregulation of tsc2 by rosiglitazone was associated with inhibition of mtor signaling as determined by evaluating the phosphorylation state of p70s6k, a downstream target of mtor. to determine the exact contribution of tsc2, we tested tumor cells transfected with control and tsc2 sirnas. as shown in figure 3(a), the tsc2 sirna blocked tsc2 protein production, while the control sirna had no effect. armed with these tools, we tested the effects of rosiglitazone on p70s6k. as expected, upregulation of tsc2 by rosiglitazone coincided with downregulation of phosphorylated p70s6k (figure 3(b)). silencing of tsc2 by sirna induced phosphorylation of p70s6k at baseline and inhibited p70s6k downregulation in the presence of rosiglitazone demonstrating a direct link between tsc2 induction and inhibition of mtor signaling (figure 3(b)).",pmc1892639,1,10,19,1,29
2272,p110α,protein,,pik3ca,uniprot,,,,ras,protein,,,,,,,positive,d,interaction,,,fibroblast,mouse embryonic,mouse,['3619'],nan,nan,"to determine the specific functions of p110α, mice carrying a conditionally targeted allele of the pik3ca gene were generated [311]. pik3ca-knockout mouse embryonic fibroblasts were deficient in cellular signaling in response to various growth factors and resistant to oncogenic transformation induced by a variety of oncogenic receptor tyrosine kinases, indicating a fundamental role for p110α in these biological processes [311]. in a recent study, mice with mutations in the pik3ca gene that block its interaction with ras were generated [312]. cells from these mice showed proliferative defects and selective disruption of signaling from growth factors to pi3k. importantly, the mutant mice were highly resistant ras oncogene-induced tumorigenesis [312]. the interaction of ras with p110α was thus demonstrated to be required in vivo for normal growth factor signaling and for ras-driven tumor formation [312].",pmc2652403,1,10,19,1,29
719,chk2,protein,kinase,chek2,uniprot,o96017,nucleus,go:0005634,e2f1,protein,transcription factor,e2f1,uniprot,,nucleus,go:0005634,positive,d,phosphorylation,s364,,,,,['1654'],nan,nan,"the transcription factor e2f1 is also activated by phosphorylation in response to dna damage. atm and chk2 phosphorylate e2f1 on s31 and s364, respectively, which leads to e2f stabilization [84,85]. accumulation of e2f1 leads to increased transcription activation and apoptosis, although the specific genes that are responsible for these cellular effects have not yet been determined [84,85].",pmc2954851,1,10,19,1,29
3411,tsc2,protein,wild-type,tsc2,uniprot,p49815,cytoplasm,go:0005737,irs-1,protein,,irs1,uniprot,p35568,cytoplasm,go:0005737,negative,d,phosphorylation,ser302,mefs,fibroblast,,mouse,['706'],nan,nan,"−/− mefs lines in which wild-type (−/− (+wt)) or a pathogenic mutant tsc2 (−/− (+n1643k)) has been reintroduced; top, ser302-phosphorylated irs-1; bottom, total irs-1. (f) irs-1 ser302 phosphorylation is inhibited by mtor/s6k inhibition with rapamycin in serum-starved tsc2",pmc2172316,1,10,19,1,29
475,c-src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,nox1,protein,,nox1,uniprot,q9y5s8,plasma membrane,go:0005886,positive,d,phosphorylation,"tks4 (phosphorylation), noxa1 (phosphorylation)",dld1,colon cancer,colon,human,['1384'],nan,nan,"we have previously shown that in human dld1 colon cancer cells and other cancer cell lines there is a correlation between the levels of c-src activity and their ability to generate ros (gianni et al., 2008), yet the exact relationships between src activity, ros formation, carcinogenesis, and metastasis remain poorly defined. metastatic cancer cells have the ability to both migrate to and degrade the ecm, and invasiveness has been correlated with the presence of invadopodia (linder, 2007; gimona et al., 2008), as well as ros production (okada et al., 2006). src activity and production of ros via nadph oxidase have been shown to be required for the formation of functional invadopodia in several cancer cells, including human dld1 colon cancer cells. however, the signals and molecular mechanisms by which src induces the redox-dependent generation of invadopodia are still a matter of investigation. in this study, we elucidate the relationship between src phosphorylation of tks4 and noxa1 and the nox1-dependent formation of invadopodia and ecm degradation in dld1 cells. interestingly, we show that the overexpression of tks4 and noxa1 unphoshorylable mutants reduces the ability of dld1 cells to form ecm-degrading invadopodia in presence of active src. on the contrary, the presence of tks4 and noxa1 phosphomimetic mutants is able to partially restore this phenotype even in absence of active src.",pmc2993755,1,10,19,1,29
449,braf,protein,oncogene,braf,uniprot,p15056,cytoplasm,go:0005737,autophagy,process,,,,,cytoplasm,go:0005737,positive,d,induction,,melanoma cells,,melanoma,melanoma,['3509'],nan,nan,"although hyperactivation oncogenic braf induces macroautophagy (hereafter referred to as autophagy) in melanoma cells [39], markers of autophagy activation, including conversion of lc3-i to lc3-ii and aggregation (punctate staining) of gfp-lc3 that was stably introduced into cells by lentiviral transduction, could hardly be detected in brafv600e as well as brafwt melanoma cells (figures 4a and b). however, inhibition of the autophagy flux at late stages by bafilomycin a1, which inhibits fusion of autophagosomes with lysosomes, resulted in accumulation of lc3-ii and increases in p62, a receptor for cargos destined to be degraded by autophagy that would otherwise be decreased by lysosomal degradation of autophagosomes (figure 4b) [40], in both brafv600e and brafwt melanoma cells. thus, the autophagy flux is constitutively activated at low levels in melanoma cells irrespective of their braf mutational status.",pmc4294377,1,10,19,1,29
383,b-raf,protein,,braf,uniprot,p15056,plasma membrane,go:0005886,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,negative,d,inhibition,,melanoma,cancerous,melanoma,human,['2456'],nan,nan,"we examined the serum-dependent proliferation of multiple human melanoma cell lines and the effects of inhibition of b-raf by bay43-9006 and of mtor by rapamycin. melanoma cell lines were tested for proliferation after treatment with a single dose of bay43-9006 or rapamycin using cell titer-glo (promega corporation, madison, wi), a luminescence-based atp cell viability assay. cells were exposed to different doses of either drug for one hour. then, the media was changed and the cells were cultured for two days in the presence of serum. we found that micromolar concentrations were cytotoxic, because cell numbers decreased after two days, whereas nanomolar concentrations were growth inhibitory. melanoma cells showed dose-dependent inhibition with 0.01 nm to 100 nm of bay43-9006 (figure 2a), or rapamycin (figure 2b). proliferation of the cells was inhibited in either 5% or 0.5% serum.",pmc1289294,1,10,19,1,29
382,b-raf,protein,,braf,uniprot,o75376,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,negative,d,inhibition,,melanoma,,skin,human,['2445'],nan,nan,"serum-stimulated proliferation of multiple human melanoma cell lines was inhibited by bay43-9006 and by rapamycin. melanoma cells containing the b-raf mutation v599e were more sensitive than cells with wild-type b-raf to 10 nm doses of both bay43-9006 and rapamycin. regardless of b-raf mutational status, the combination of low dose rapamycin and bay43-9006 synergistically inhibited melanoma cell proliferation. as expected, rapamycin inhibited the phosphorylation of mtor substrates, p70s6k and 4ebp1, and bay43-9006 inhibited phosphorylation of erk, which is dependent on b-raf activity. we also observed unexpected rapamycin inhibition of the phosphorylation of erk, as well as bay43-9006 inhibition of the phosphorylation of mtor substrates, p70s6k and 4ebp1.",pmc1289294,1,10,19,1,29
210,akt,protein,,,uniprot,p31749,,,p53,protein,,tp53,uniprot,p04637,nucleus,go:0005634,positive,d,phosphorylation,s166-mdm2,,,,,['398'],nan,nan,"although we have focused on the akt mediated regulation of p53mut stability, the observation that regulation of npm oligomerisation governs arf localization may also be a direct mechanism which facilitates p53 stabilization following oncogene activation in the absence of dna damage [19]. in the absence of additional mutations, oncogene activation leads to p53 stabilization and the induction of cellular senescence. furthermore, growing evidence suggests that akt activity can mediate p53 stabilization and induction of senescence [85-87]. akt is known to directly phosphorylate s166-mdm2 leading to enhanced activity and reduced p53 levels, which in agreement with previous studies where observations were made in cells with ink4a/arf deletions [58, 59], we find akt inhibition increases p53 levels in arf null mcf7 cells (fig. s3g). importantly, we find that expression of arf stabilizes p53 but is now subject to npm mediated control and akt inhibition decreases p53 levels. this is in line with emerging evidence where constitutive activation of akt has been demonstrated to inhibit mdm2 activity [85]. moreover, we find that correlations exist between akt activity and p53 levels in breast and pancreatic cancer cohorts, and are dependent on cdkn2a expression levels (table s2). this is a relevant point for the administration of akt inhibitors in the clinic where efficacy is likely to rely on arf status as well as p53mut.",pmc4171619,1,10,19,1,29
209,akt,protein,,,uniprot,p31749,,,p16,protein,,cdkn2a,uniprot,q15631,,,negative,d,induce,,"bj-t, imr90",fibroblast,,,['3363'],nan,nan,"in addition, we demonstrate that, unlike ras, akt fails to induce high levels of p16 or sahfs in either bj-t or imr90 cells. although the levels of p16 have been shown to be an important determinant for ras-induced senescence (benanti and galloway, 2004), our data indicate that p16 is unlikely to play a role in akt-induced senescence. rapid induction of senescence without signs of dna damage, p16 accumulation or sahf formation has similarly been reported for the oncogenic fusion protein runx1-eto (wolyniec et al., 2009). the p16-dependent alterations to chromatin structure, detected as sahfs, are thought to promote the irreversibility of the cell cycle arrest due to stable silencing of pro-proliferative genes (narita et al., 2003). it is not clear as to how the absence of sahfs would affect the maintenance of the senescence phenotype of akt cells in vivo. however, here we demonstrate that both akt and ras induce a robust senescence-associated secretory phenotype, which may function to maintain senescence (freund et al., 2010). identification of these distinctly different mechanisms for p53-dependent senescence induction by active ras and akt reinforce the concept that specific oncogenic signalling modules may target distinct mediators of senescence.",pmc3325598,1,10,19,1,29
205,akt,protein,,,uniprot,p31749,,,caspase 9,protein,,,uniprot,p55211,,,negative,d,phosphorylation,ser-196,,,,human,['949'],nan,nan,"vehicle-treated hcc-1954 and mcf-7 cells express high levels of active akt (pakt) and phosphorylated downstream substrates gsk (pgsk), bad (pbad), and caspase 9 (pcaspase-9). treatment of hcc-1954 (20 μm) and mcf-7 cells (40 μm) with α-tea for 9, 15, and 24 h: (1) reduces levels of pakt (both ser-473 and ser-308) as well as its downstream substrates pgsk (α/β) (ser-21/9), pbad (ser-136), and pcaspase-9 (ser-196) and increases cleaved caspase 9 in a time-dependent manner (figure 2a), (2) downregulates perk1/2 and its substrates pp90sk (ser-380) and pbad (ser-112) (figure 2b), and (3) downregulates pmtor (ser-2448) and its substrates pp70s6k (thr-389) and p4e-bp1 (thr-37/46) (figure 2c). these data show that α-tea suppresses the active forms of akt, erk, mtor, and their downstream substrates, resulting in activation of proapoptotic mediators bad and caspase-9.",pmc3039802,1,10,19,1,29
1084,erk,protein,extracellular signal-regulated kinase,,uniprot,,cytoplasm,go:0005737,rac1,protein,small gtpase,,uniprot,,cytoplasm,go:0005737,positive,d,phosphorylation,108t,,,,,['1520'],nan,nan,"we have previously shown that extracellular signal-regulated kinases [erk, consisting of p44 (erk1) and p42 (erk2)] phosphorylates 108t of rac1 in response to egf stimulation [21]. this phosphorylation alters rac1 activity, its subcellular localization and its role in mediating cell migration. it has been well established that the substrate selectivity of erks is dependent on erk-docking sites (d-sites), with the core consensus motif (k/r)1-3-x1-6-φ-x-φ (where φ is a hydrophobic residue) located on erk-interacting proteins [22,23]. we have also shown that the direct interaction between rac1 and erk is mediated through the erk docking site in the rac1 c-terminus [21]. it is interesting to note that rhoa also contains a putative erk docking site (d-site) in its c-terminal 185kkksgclll193.",pmc4729484,1,10,19,1,29
1101,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,negative,d,phosphorylation,t125,,,,human,['295'],nan,nan,"erk phosphorylation of caspase-9 inhibits caspase-9 proteolytic activity and provides another mechanism by which activated erk proteins mediate cell survival [2]. the effects of test compounds on erk-mediated phosphorylation of caspase-9 on t125 were examined by immunoblotting lysates from cells where the erk pathway was stimulated with egf. apoptosis-inducing test compounds 76, 76.2, 76.3, and 76.4, inhibited caspase-9 phosphorylation by 50-60% in treated cells (figure 6a). next, active erk2 was incubated with caspase-9 protein in the absence or presence of test compounds and phosphorylation was examined using in vitro kinase assays. figure 6b shows that compounds 76, 76.2, 76.3, and 76.4 inhibited erk-mediated phosphorylation of caspase-9 in a dose dependent manner. while 76.3 appeared to be the more potent inhibitor of caspase-9 phosphorylation, there was no statistical difference between compounds at any of the doses.",pmc3025971,1,10,19,1,29
1102,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,cyclin d1,protein,,ccnd1,uniprot,p24385,nucleus,go:0005634,positive,d,regulation,transcription promoter binding sites,,lung adenocarcinoma,lung,human,['2352'],nan,nan,"an extensive list of signaling pathways regulate cyclin d1 and its transcription promoter binding sites.32 erk, a major downstream effector of ras, is strongly associated with cell cycle entry particularly for the induction of cyclin d1 expression via downregulation of p27kip1.33,34 conversely, cyclin d1 activity is independent of erk expression.34 in our experiment, cink4 reduced cyclin d1, but did not affect its upstream regulator, phosphorylated erk. these results suggest that the relationship between cyclind1 and erk is not a simple unidirectional linear one, at least in lung adenocarcinoma with kras mutations.",pmc3742489,1,10,19,1,29
1659,irs-1,protein,,irs1,uniprot,p35568,,,pkb,protein,,akt1,uniprot,p31749,,,positive,d,activation,,mefs,,,,['700'],nan,nan,"−/− mefs after overexpression of irs-1 or irs-2. we find that overexpression of either irs-1 or irs-2 results in an increase in pkb activation, which when combined with short-term inhibition of mtor/s6k signaling using rapamycin leads to a phenocopy of the effect of sustained (24 h) treatment with rapamycin (fig. 4 f).",pmc2172316,1,10,19,1,29
2137,mutant kras,protein,,,uniprot,p01116,,,erk,protein,,mapk1,uniprot,p28482,,,positive,d,inhibition,,,nsclc,lung,human,['2632'],nan,nan,"the exact influence of statins on gefitinib resistance in human non-small cell lung cancer (nsclc) cells with kras mutation alone or kras/pik3ca and kras/pten comutations remains unclear. this work found that transfection of mutant kras plasmids significantly suppressed the gefitinib cytotoxicity in calu3 cells (wild-type kras). gefitinib disrupted the kras/pi3k and kras/raf complexes in calu3 cells, whereas not in calu3 kras mutant cells. these trends were corresponding to the expression of pakt and perk in gefitinib treatment. atorvastatin (1 μm) plus gefitinib treatment inhibited proliferation, promoted cell apoptosis, and reduced the akt activity in kras mutant nsclc cells compared with gefitinib alone. atorvastatin (5 μm) further enhanced the gefitinib cytotoxicity through concomitant inhibition of akt and erk activity. atorvastatin could interrupt kras/pi3k and kras/raf complexes, leading to suppression of akt and erk activity. similar results were also obtained in comutant kras/pten or kras/pik3ca nsclc cells. furthermore, mevalonate administration reversed the effects of atorvastatin on the kras/raf and kras/pi3k complexes, as well as akt and erk activity in both a549 and calu1 cells. the in vivo results were similar to those obtained in vitro. therefore, mutant kras-mediated gefitinib insensitivity is mainly derived from failure to disrupt the kras/raf and kras/pi3k complexes in kras mutant nsclc cells. atorvastatin overcomes gefitinib resistance in kras mutant nsclc cells irrespective of pik3ca and pten statuses through inhibition of hmg-coa reductase-dependent disruption of the kras/raf and kras/pi3k complexes.",pmc3789171,1,10,19,1,29
1821,mek,protein,,,uniprot,,,,nras q61r,protein,mutant,nras,uniprot,p01116,,,negative,d,inhibition,mek signaling,,melanoma,,human,['156'],nan,nan,"additionally, we examined the effects of mek inhibition in two independent mutant nras q61r melanoma patient biopsy samples, tjumel-35 and tjumel-36 (figure s2a–b). pieces of biopsy sample were cultured on hemostatic gelatin sponges partially submerged in medium in an ex vivo explant system. trametinib treatment of explants showed inhibition of mek signaling, increased akt phosphorylation and decreased mig6 expression through western blot analysis (figure 1c). immunohistochemistry showed inhibition of erk1/2 phosphorylation and a decrease in mig6 staining (figure 1d). increased akt phosphorylation, as detected by ihc staining, was variable across the tumor sample perhaps due to differing levels of mek inhibition.",pmc4789776,1,10,19,1,29
1808,mek,protein,,map2k,uniprot,p36507,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,activation,,,melanoma,,human,['153'],nan,nan,"to study altered signaling responses to mek inhibition in mutant nras melanoma, we utilized reverse phase protein arrays (rppa). in mek-inhibited mutant nras melanoma cells, we detected an increase in akt activation and a decrease in the adaptor protein, mitogen-inducible gene 6 (mig6). mig6 is a non-kinase cytosolic scaffolding protein that binds to erbb family receptors and inhibits their catalytic activity by blocking the formation of an activating dimer (zhang et al, 2007). additionally, mig6 mediates receptor endocytosis (frosi et al, 2010, walsh and lazzara, 2013) and lysosomal degradation (ying et al, 2010). we identified a role for mig6 as a negative regulator of egf-induced akt and erk1/2 signaling and cell migration and invasion in mutant nras melanoma. in the presence of mek inhibition, mig6 did not modulate growth or apoptosis in mutant nras melanoma cells. rather, mig6 expression decreased cell migration and invasion; its further depletion in mek-inhibited cells increased migration and invasion. therefore, the decrease in mig6 in the presence of mek inhibition may be a pro-invasive stimulus in mutant nras melanoma.",pmc4789776,1,10,19,1,29
1716,kras,protein,,,uniprot,p01116,,,pi3k p110α,protein,,,uniprot,p42336,,,positive,d,binds,,"a549, calu1",epithelial,lung,human,['2650'],nan,nan,"as shown in figure 4a, immunostaining of a549 cells and calu1 cells with kras and pi3k p110α antibodies revealed that kras and the pi3k p110α subunit were well overlapped in these cells. interestingly, when pik3ca e545k plasmid or pten shrna was transfected into these cells, kras and p110α were also well overlapped. to confirm that kras directly interacts with the pi3k p110α subunit in kras mutant cells irrespective of pik3ca and pten statuses, we performed immunoprecipitation assay. as shown in figure 4b, kras directly bound with the pi3k p110α subunit in a549 cells, and transfection with pik3ca e545k plasmid or pten shrna enhanced such interaction corresponded with increased kinetics of the pi3k/akt pathway. consistent results were also obtained in another kras mutant cell line calu1 (figure 4c).",pmc3789171,1,10,19,1,29
1708,kras,protein,,kras,uniprot,p01116,cytoplasm,go:0005737,erk,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,positive,d,phosphorylation,t205,,pancreatic,,human,['645'],nan,nan,"kras mutation has been regarded as the most frequent oncogenic event in pdac. overall, oncogenic kras signaling in pdac is through three major pathways: raf/mek/erk, pi3k/pdk1/akt and the ral guanine nucleotide exchange factor pathway25. as the best characterized ras downstream pathway, the mapk signaling axis is of particular importance in pdac development17. the pathway has been reported to play a central role in diverse cellular responses, such as proliferation, differentiation, and survival. briefly, activated ras binds to raf, thereby directly activating mek kinase via phosphorylation. mek1/2 subsequently phosphorylates residues in the activation loops of erk kinase, resulting in their activation. upon activation, erk kinase can phosphorylate and activate both cytosolic and nuclear targets18. previously, minella et al.20 indicated that ras stabilized cyclin e via the activation of the mapk pathway and inhibition of fbw7-dependent cyclin e ubiquitination in vivo. however, the underlying mechanism was not further clarified. inspired by their findings, we speculated that cross-talk may occur between fbw7 and the mapk pathway. as expected, in the current study, we found that fbw7 levels are inversely correlated with erk activation in pdac. on one hand, ectopic expression of erk1 significantly reduced the endogenous fbw7 protein level. on the other hand, inhibition of the mapk pathway dramatically increased endogenous fbw7 abundance. by contrast, inhibition of akt kinase dramatically shortened fbw7 half-life, indicating the pi3k/akt pathway may play a different role in regulating fbw7 stability (supplementary information, figure s3f and s3g). furthermore, we found that erk directly interacts with fbw7 and phosphorylates the t205 site to destabilize fbw7. before our study, a report demonstrated that pin1, the only peptidyl-prolyl cis/trans isomerase, interacts with fbw7 in a phospho-t205-dependent manner and promotes fbw7 self-ubiquitination and protein degradation21. however, the signaling to trigger t205 phosphorylation, which is important for understanding the physiological regulation, was largely left untouched in that study. hence, our research not only filled the missing upstream signaling that controls fbw7 stability via the t205 site but also identified new functions of the kras-mapk kinase pathways in pdac. interestingly, a similar regulation paradigm between other oncogenic kinase and tumor suppressing proteins has also been reported. for example, decreased p27 expression levels in tumor cells mostly occur due to enhanced proteolysis, given that mutation of the p27 gene is a rare event in cancer. this low expression level is well explained by the finding that cylin a/cdk2 phosphorylates the cdk inhibitor p27 and triggers its destruction by the oncoprotein scf-skp2 in many cancer types26, such as oral squamous cell carcinoma27. another example is that the oncoprotein nedd4-1 negatively regulates the stability of the tumor suppressor pten by catalyzing pten polyubiquitination and destruction in lung cancer28,29. thus, in addition to genetic mutations, accelerated protein turnover upon certain post-translational modification is another important means by which oncoproteins inactivate tumor suppressors during tumorigenesis. to dissect a possible role of self-ubiquitination in erk-mediated fbw7 degradation, we generated a fbw7 r465h mutant that could not ubiquitinate substrates based on a previous report21. as shown in supplementary information, figure s7a, r465h is more heavily ubiquitinated than wt fbw7, which is consistent with the previous report. co-transfected erk kinase could still promote poly-ubiquitination of the r465h mutant, which possibly indicates the involvement of other e3 ligases in fbw7 stability control, but the possibility of self-ubiquitination can not be formally excluded. furthermore, we generated t205e fbw7 construct. as shown in supplementary information, figure s7b, t205e mutant failed to form homo-dimer as wt and t205a fbw7 did. we also tested the ubiquitination potential of t205e, and interestingly t205e are less ubiquitinated than wt (supplementary information, figure s7c). although the t→e mutation generated a negative charge at aa205, which is similar to what a phosphor group does after phosphorylation, pin1 isomerase does not interact with ep motif and could not perform the cis-trans conversions. thus, the t205e mutant may not be appropriate to be used to evaluate the regulatory effect involving pin1. overall, our study established an important regulatory function of fbw7 by the activated ras-mapk-erk signaling pathway, although more efforts are required to dissect how fbw7 is ubiquitinated after its phosphorylation.",pmc4423074,1,10,19,1,29
1707,kras,protein,,kras,cosmic,,,,cdkn2a,gene,p16,cdkn2a,cosmic,,,,negative,d,homozygous deletions,,,nsclc,,human,['2358'],nan,nan,"nsclc cell lines a549 (krasg12s), h358 (krasg12c), sklu-1 (krasg12s), h23 (krasg12c), and pc14 (kraswild) were obtained from the korea cell line bank. h358 and h23 cells carry a wild-type cdkn2a (p16) gene, but a549, sklu-1, and pc14 carry homozygous deletions of the cdkn2a gene. the somatic mutation data for kras and cdkn2a were obtained from the cosmic database (http://www.sanger.ac.uk/cosmic).16,48 a549 and sklu-1 were propagated in dulbecco’s modified eagle medium (dmem, gibco brl). h358, h23, and pc14 cells were maintained in rpmi 1640 medium (welgene). culture media were supplemented with 10% fetal bovine serum (fbs; gibco brl), 1% penicillin-streptomycin (gibco brl) and 10 mmol/l hepes (amresco). cells were cultivated in 100-mm plastic dishes (tpp) at 37 °c in 5% co2 and 95% air and harvested with trypsin/edta at logarithmic growth.",pmc3742489,1,10,19,1,29
1702,kras,protein,g12v,kras,addgene,plasmid 9052,cytoplasm,go:0005737,pik3ca,protein,e545k,pik3ca,origene technologies,rc400348,cytoplasm,go:0005737,positive,d,transfection,,nsclc,epithelial,lung,human,['2664'],nan,nan,"human nsclc cell lines (originally purchased from atcc) with documented kras mutations-a549 (kras g12s), calu1 (kras g12c), h460 (kras q61h pik3ca e545k), h157 (kras g12r pten g251c), and one kras wt nsclc cell-calu3 were used. the procedure of transfection of pbabe puro-kras g12v (addgene, cambridge, ma, usa; plasmid 9052) and the corresponding empty vector pbabe puro was strictly according to a previous report.30 human trueorf pik3ca e545k plasmid was purchased from origene technologies (rockville, md, usa; cat. no. rc400348). trueorfs have a c-terminal fusion of myc/ddk tag. the cloning expression vector is pcmv6-entry. a549 and calu1 cells were stably transfected with pik3ca e545k according to another work.31 for shrna experiments, cells stably transfected with the pretrosuper (prs; origene) and prs vector expressing shrna for pten knockdown (prs-shpten; origene; cat. no. tr320498) were preformed as that previously reported.32",pmc3789171,1,10,19,1,29
1672,jnk,protein,,mapk8,uniprot,p45983,cytoplasm,go:0005737,pi3k,protein,,pik3ca,uniprot,p42336,cytoplasm,go:0005737,negative,d,downregulation,,mcf-7 and hcc-1954,breast cancer cells,breast cancer,human,['938'],nan,nan,downregulation of irs-1/pi3k pathways via jnk are critical for α-tea and α-tea+mek or mtor inhibitor-induced apoptosis in human mcf-7 and hcc-1954 breast cancer cells.,pmc3039802,1,10,19,1,29
1668,jnk,protein,,jnk,uniprot,p45983,cytoplasm,go:0005737,mtor,protein,,mtor,uniprot,p42345,cytoplasm,go:0005737,positive,d,phosphorylation,ser-307,,,,,['953'],nan,nan,"α-tea, respectively, for 9, 15, and 24 h. α-tocopherol ether-linked acetic acid induced increased levels of pjnk2/1, increased levels of pirs-1 (ser-307), and reduced levels of total irs-1 in both cell lines (figure 4a). knockdown of jnk using a chemical inhibitor sp600125 (jnki) (figure 4b) or sirna (figure 4c) blocked the ability of α-tea to increase pirs-1 (ser-307) and decrease levels of total irs-1 protein, and suppressed the ability of α-tea to reduce pakt (ser-473), perk1/2, and pmtor (ser-2448). these data suggest that downregulation of irs-1 is involved in the ability of α-tea to suppress akt, erk, and mtor signalling and demonstrated that jnk is involved in this event via phosphorylation of irs-1 at ser-307, leading to its degradation.",pmc3039802,1,10,19,1,29
3229,src,protein,tyrosine kinase,src,uniprot,p12931,cytoplasm,go:0005737,caspase-7,protein,cysteine protease,casp7,uniprot,p55210,cytoplasm,go:0005737,positive,d,phosphorylation,,,colon cancer,,human,['980'],nan,nan,"phosphorylation is an important post-transcriptional modification for various cellular proteins. phosphoryaltion of caspases by protein kinases has been widely studied. for example, caspase-9 phosphorylation by different kinases has been reported. interestingly, tyrosine phosphorylation can increase caspase-9 activity, whereas phosphorylation of various serine or threonine sites can decrease caspase-9 activity.35 the phosphorylation of caspase-8 and -3 has also been reported.12, 13 however, the modification and regulation of caspase-7 remains poorly understood. the function of caspase-7 was long assumed to be redundant with the function of caspase-3 because of their similar structure and common protein substrates. in our previous study, we found that phosphorylation of caspase-7 is important in chemotherapeutic drug-induced apoptosis of breast cancer cells.27 interestingly, pak2 is a serine/threonine kinase, which decreases caspase-7 activity by phosphorylation. in the present study, we showed that the src tyrosine kinase can directly phosphorylate and interact with caspase-7 (figure 4), resulting in increased caspase-7 activity (figure 6). our finding is similar to the story of caspase-9 phosphorylation.35 apparently, the effect of tyrosine phosphorylation is opposite to the effect of serine/threonine phosphorylation of caspase family members. we also showed that caspase-7 is important for 5-fu induction of apoptosis independent of caspase-3 (supplementary figure 1). the relation between src and caspase-7 might explain why cells with low levels of src are more resistant to 5-fu-induced apoptosis (figure 3). importantly, antioxidants, such as nac or catalase, decrease the apoptotic effect induced by 5-fu in colon cancer cells by regulating src-dependent caspase-7 phosphorylation. taken together, our results highlight the role of src in 5-fu-induced apoptosis and provide a novel explanation as to why 5-fu is not effective in combination with some antioxidants in colon cancer patients, which is important for clinical chemotherapy.",pmc4040661,1,10,19,1,29
1117,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,apoptosis,process,,,fplx,apoptosis,cytoplasm,go:0005737,positive,d,sensitizes,,solid tumors,emptys,,human,['3247'],nan,nan,"the contribution of erk to ddr outlines a scientific background for a combinational therapy involving genotoxic drugs and mek inhibitors. as dna damage-induced erk activation inhibited ddr-associated apoptosis in myeloma and leukemia [16, 17], inhibition of erk activation will be expected to enhance the efficacy of genotoxic drugs on these cancers. however, for tumors not associated with the hematopoietic system, erk activation sensitizes dna damage-induced checkpoint activation [7, 9-15, 69, 71, 72]. therefore, inhibition of erk activation in these cancers may also enhance the genotoxic effect of chemotherapeutic drugs. this may be caused by the accumulation of dna lesions due to impaired checkpoint activation when erk activation is inhibited. this concept is supported by a recent report showing that the mek inhibitor adz6244 enhanced radiation-induced reduction of a549-derived xenograft tumors [105]. however, inhibition of erk may compromise checkpoint activation and thereby allowing cells to proliferate in the presence of dna lesions. this may lead to accumulation of mutations and thus contribute to cancer progression, which might be attributable to the resistance or the inefficiency of mek inhibitors in cancer therapy. therefore, a key factor in determining a regime of mek inhibitors and genotoxic drugs in treating solid cancers is whether this combinational therapy will lead to a catastrophic result due to inefficient repair of dna lesions or continuous cell proliferation in the presence of dna lesions.",pmc3330700,1,10,19,1,29
1643,insulin receptor isoform-a,protein,,,uniprot,p06213,cell membrane,go:0005886,egfr,protein,,egfr,uniprot,p00533,cell membrane,go:0005886,positive,d,inhibition,"y845, y1068, y1173",,,,human,['1404'],nan,nan,"in colorectal cancer cells, sensitivity to an anti-egfr drug (i.e., gefitinib) can be improved by the pharmacological inhibition of insulin receptor isoform-a [97]. in this case, y845, y1068, and y1173 are employed as diagnostic markers for the active state of egfr. the anti-tumor effect of gefitinib and anastrozole has been investigated in estrogen-receptor-positive breast cancer cells, where the extent of y845 phosphorylation is used as one of the outcomes of the drug treatments [98]. the anti-cancer pro-apoptotic function of an indole compound, 3,3′-diindolylmethane, toward ovarian cancer cells also involves the suppression of the y845 phosphorylation of egfr and the subsequent erk/mapk signaling pathway [99]. specific inhibition of y845 phosphorylation by the src-specific inhibitor pp2 was also shown in cervical carcinoma cells hela and siha [100], and in ionizing irradiation-treated mda-mb-468 breast cancer cells [101]. x-radiation-induced dna synthesis in rat hepatocytes was additionally shown to involve y845 phosphorylation [102].",pmc3709701,1,10,19,1,29
1588,igf-1,protein,,,uniprot,p05019,extracellular region,go:0005576,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,positive,d,regulates,,mefs,fibroblast,,human,['717'],nan,nan,−/− (white bars) mefs after 8 h in serum-free medium alone (−) or supplemented with 200 ng/ml igf-1 (+) in untreated mefs or mefs pretreated for 36 h with 20 nm rapamycin. the results are from four random 10× fields and are typical of experiments performed twice. (d) relative cell survival of tsc2,pmc2172316,1,10,19,1,29
1580,igf-1,protein,,igf1,uniprot,p05019,extracellular space,go:0005615,pkb,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,activation,,mefs,fibroblast,,human,['696'],nan,nan,"−/− (white bars) mefs after igf-1 stimulation in untreated cells or cells pretreated for 24 h with 20 nm rapamycin. results from triplicate determinations (means and sds) are shown normalized to control unstimulated samples and are representative of three independent experiments. (e) pkb activation after rnai-mediated inhibition of irs-1, irs-2, irs-1 plus irs-2, or a combination of scrambled irs-1 and irs-2 sirna (scrambled) in tsc2",pmc2172316,1,10,19,1,29
1579,igf-1,protein,,igf1,uniprot,p05019,extracellular space,go:0005615,cyclin d1,protein,,ccnd1,uniprot,p24385,nucleus,go:0005634,positive,d,stimulates,,,cancer,breast,human,['2976'],nan,nan,"igf-1 stimulates erk and akt activities and elevates cyclin d1 expression. a-b: (a) lm2 or (b) jf32 cells were cultured in serum-free media, with or without 2 ng/ml migf-1 or megf, and cell homogenates were probed for protein expression. c-e: densitometry from western blot replicates from lm2 and jf32 cell lines was combined, and presented as fold change (mean ± sem) from untreated vehicle control lanes at each time point. * p < 0.05, ** p < 0.01 and *** p < 0.001 versus control (veh -) cells at each time point by 2-way anova.",pmc3135566,1,10,19,1,29
1578,igf-1,protein,,igf1,uniprot,p05019,extracellular,,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,positive,d,survival factor,,,,,,['719'],nan,nan,"next, we tested the ability of igf-1 to act as a survival factor for tsc2",pmc2172316,1,10,19,1,29
1577,igf-1,protein,,igf1,uniprot,p05019,extracellular,go:0005615,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,positive,d,stimulated chemotaxis,,mefs,,,,['716'],nan,nan,−/− (white bars) mefs. the results are expressed as a percentage of that of igf-1–stimulated chemotaxis of tsc2,pmc2172316,1,10,19,1,29
1168,erk2,protein,,mapk1,uniprot,p28482,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,negative,d,inhibit,,hela,epithelial-like,,human,['296'],nan,nan,"test compounds inhibit erk-mediated phosphorylation of caspase-9 in cells and in in vitro kinase assays. (a) hela cells transfected with caspase-9 (c287a) were pre-treated for 1 hour with 50 um of indicated test compound, stimulated with egf (25 ng/ml), and immunoblotted for phosphorylated caspase-9 (pt125) or total caspase-9. graph shows the mean ± sem for relative phosphorylation as determined by densitometry scanning from 3 independent experiments. (b) in vitro kinase assays examining 32p incorporation into caspase-9 following incubation with active erk2 and γ-32p-atp for 60 min. in the absence or presence of 1-25 μm of the indicated test compound. relative phosphate incorporation was quantified by phosphoimager analysis. data show the mean ± sem of three independent experiments. * and # indicates statistical significance compared to egf-only treatment (a) or untreated controls (b), p ≤ 0.05 and p ≤ 0.01, respectively. c, untreated control; (-), egf treated control; u, u0126",pmc3025971,1,10,19,1,29
1119,erk,protein,,,uniprot,p27361,cytoplasm,go:0005737,caspase-9,protein,,casp9,uniprot,p55211,cytoplasm,go:0005737,negative,d,prevent inactivation,,,,,,['298'],nan,nan,"our data support a mechanism by which the erk-targeted compounds prevent inactivation of caspase-9 and p90rsk-1 phosphorylation of bad (figures 4 and 6). both caspase-9 and p90rsk-1 contain d-domains that are thought to form contacts with the cd domain of erk proteins [1,24]; the region predicted to be targeted by the test compounds. structural studies underway are determining the site of interactions between the compounds and erk proteins to better understand the mechanisms of inhibition and identify chemical features that can be modified to improve inhibitor binding and efficacy. a region analogous to the cd domain of erk can be found on other map kinases family members including p38 and jnk [29,42]. the subtle differences between these regions are determinants of substrate selectivity between the map kinases. in addition, differences in the residues associated with the d-domains of map kinase interacting proteins can confer selectivity. for example, the differences in d-domains on map kinase kinase (mkk) proteins appear to be important for determining what map kinase the mkk isoform will target [43].",pmc3025971,1,10,19,1,29
3192,src,protein,,src,uniprot,p12931,cytoplasm,go:0005737,akt,protein,,akt1,uniprot,p31749,cytoplasm,go:0005737,positive,d,activation,,llc-pk1,epithelial,kidney,unspecified,['2064'],nan,nan,"it is known that ouabain also stimulates pi3k/akt pathways in llc-pk1 and other cells, and that the activation of src is important for the full activation of akt [20, 29]. to further verify the inhibitory effects of yfp-cd2 on ouabain-induced signal transduction, we exposed both control and cd2-2 cells to different concentrations of ouabain and measured akt activation by western blot analysis of cell lysates. as depicted in fig 4c, ouabain-induced akt activation was significantly attenuated by the expression of yfp-cd2. thus, yfp-cd2 appears to work as a dominant negative mutant, capable of blocking ouabain-induced signal transduction including the activation of src, erks and akt.",pmc4638348,1,10,19,1,29
3399,tsc2,protein,,tsc2,uniprot,p49815,cytoplasm,go:0005737,tsc2,protein,phosphorylated,tsc2,uniprot,p49815,cytoplasm,go:0005737,positive,d,phosphorylation,,,b-cell,,human,['2264'],nan,nan,"western blotting was performed as previously described [15]. briefly, protein concentrations were determined by the bio-rad protein assay. equal amounts of protein from whole cell lysates were solubilized in 2x sds-sample buffer and separated on sds-8% polyacrylamide gels. blots were incubated with antibodies raised against tsc2 and phosphorylated tsc2 (1:2000), p38 mapk and phosphor-p38 mapk, p70s6k and phosphor-p70s6k (1:1000). the blots were washed and followed by incubation with a secondary goat antibody raised against rabbit igg conjugated to horseradish peroxidase (1:2000, cell signaling, beverly, mass, usa). the blots were washed, transferred to freshly made ecl solution (amersham, arlington, ill, usa) for 1 minute, and exposed to x-ray film. in controls, the antibodies were omitted or replaced with a control rabbit igg.",pmc1892639,1,10,18,1,28
2429,p70s6k,protein,,,uniprot,p23443,,,s6,protein,,,uniprot,p62753,,,negative,d,inhibition,,,nsclc,lung,human,['3033'],nan,nan,"in conclusion, our study demonstrated that the p70s6k inhibitor pf-4708671 could affect cell cycle distribution, inhibiting cell proliferation, apoptosis and invasion in nsclc cells. inhibiting the p70s6k-s6 axis resulted in potent anti-tumor activity. therefore, combination therapy with p70s6k inhibitor and chemotherapy represents a promising new strategy for nsclc treatment.",pmc4714881,1,10,18,1,28
3056,s6k1,protein,,s6k1,uniprot,p23443,,,rps6,protein,ribosomal,rps6,uniprot,p62753,cytosol,go:0005829,positive,d,phosphorylation,c-terminal serine sites,,,,,['1438'],nan,nan,"the ribosomal protein s6 (rps6) was the first identified substrate of s6k. it is phosphorylated on five c-terminal serine sites by s6ks in the following sequential order: s236 > s235 > s240 > s244 > s247 [65]. the study of rps6p/− knock-in mice (in which alanine residues replaced the rps6 phosphorylation sites) established that rps6 phosphorylation is crucial for cell size and proliferation since cells isolated from rps6p−/− displayed defective cell growth [66, 67]. s6k1 is very essential for regulating cell and body size as s6k1 null mice are much smaller at birth because of a decrease in the size of all organs [66] and a majority of ds6k null drosophila show embryonic lethality [68]. the study of rps6p−/− mice has also confirmed that the translation of mrnas having a 5′ terminus oligopyrimidine tract (5′top mrnas), a process that was earlier considered to be regulated by rps6 phosphorylation, is not dependent on this event [69].",pmc4258317,1,10,18,1,28
1656,irs-1,protein,,irs1,uniprot,p35568,cytoplasm,go:0005737,irs-1,protein,,irs1,uniprot,p35568,cytoplasm,go:0005737,negative,i,feedback regulation,,,,colorectal,human,['1263'],nan,nan,"given that little has been studied on the phosphorylation state of irs-1 in crc these results should be of great interest for future research. the negative regulation of irs-1 is well documented 20, 27 and our data suggests that as crc progresses the negative feedback loops regulating irs-1 signaling are still active. as to the over expression of irs-1 in crc, miranda identifies 56 mirnas that are predicted to target irs-1. we measured 26 and found 9 to be significantly depressed.",pmc3187934,1,10,18,1,28
704,checkpoint kinase 2 (chk2),protein,kinase,chek2,uniprot,o96017,nucleus,go:0005634,chk2,protein,kinase,chek2,uniprot,o96017,nucleus,go:0005634,positive,i,phosphorylation,threonine 68,,,,,['1148'],nan,nan,"checkpoint kinase 2 (chk2) is a central dna damage checkpoint regulator [7], [8], responding mostly to stimuli that cause double strand breaks, such as ionizing radiation or topoisomerase ii inhibitors such as doxorubicin. the kinase atm is involved in sensing the damage and initiating the checkpoint response [9]. among other substrates, atm phosphorylates chk2 on threonine 68 [10], [11], inducing dimerization of chk2 and auto-phosphorylation of multiple sites, leading to full activation [12]–[15]. chk2 activation results in cell cycle arrest [16] and activation of the dna repair process [17], [18]. finally, if the damage is too extensive to be repaired, chk2 is able to induce apoptosis, through phosphorylation of the pro-apoptotic transcription factors p53 [19], [20] and e2f1 [21].",pmc3656868,1,10,18,1,28
722,chk2,protein,,chek2,uniprot,o96017,chromatin,go:0000785,chk2,protein,,chek2,uniprot,o96017,chromatin,go:0000785,positive,d,"phosphorylation, ubiquitinylation","activating t-loop, broken chromatin",,,,,['33'],nan,nan,"structural information about chk2, from crystallography and mass spectrometry, has permitted the discovery of new phosphorylation (king et al., 2006; guo et al., 2010) and ubiquitinylation events (lovly et al., 2008) involved in the activation of chk2. a strict, spatiotemporally regulated sequence of phosphorylations within the activating t-loop was shown to control chk2 kinase activity and modulate its recognition of phosphorylation targets and its localization on chromatin (guo et al., 2010). this study showed that chk2 is transiently retained on broken chromatin, suggesting that it also participates in the repair of lesions. another study reported that chk2 autophosphorylates on ser379, an event that facilitates chk2 ubiquitinylation by an e3 ligase complex containing cullin 1 (lovly et al., 2008).",pmc4296918,1,10,18,1,28
727,chk2,protein,,chek2,uniprot,o96017,,,chk2,protein,,chek2,uniprot,o96017,,,negative,i,dephosphorylation,,,,,,['37'],nan,nan,"chk2 may also be deactivated by dephosphorylation by the phosphatases that normally maintain this protein in an inactive state in the absence of dna damage, such as pp2a (freeman et al., 2010) and wip1 (fujimoto et al., 2006; oliva-trastoy et al., 2007). a third way in which chk2 is deactivated involves phosphorylation of the fha domain by polo-like kinase-1 (plk1; van vugt et al., 2010) that reduces its ability to bind phosphorylated proteins, including other chk2 molecules.",pmc4296918,1,10,18,1,28
747,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,positive,d,phosphorylation,,,,,,['30'],nan,nan,"chk2 was discovered in 1998 as the mammalian homolog of saccharomyces cerevisiae rad53 and schizosaccharomyces pombe cds1 kinases that are active in the yeast ddr (matsuoka et al., 1998). the protein is conserved in mouse, rat, zebrafish, xenopus laevis, drosophila melanogaster, and caenorhabditis elegans. in humans, it is a single 65 kda polypeptide of 543 residues with three distinct functional domains (figure 2a). at the n-terminus, there is a region rich in serine-glutamine and threonine-glutamine pairs, called sq/tq cluster domain (scd); these sq/tq motifs are sites of phosphorylation by pi3k family kinases including atm and atr (buscemi et al., 2006; matsuoka et al., 2007). between residues 112 and 175, a forkhead-associated (fha) domain is responsible for the interactions with phosphorylated proteins, including the phosphorylated scd of another chk2 molecule (li et al., 2002). both scd and fha domains are common components of ddr proteins. in the c-terminal half of chk2, a canonical kinase domain spans residues 220–486. like many protein kinases, chk2's catalytic function is activated by the phosphorylation of a polypeptide region (named activation loop or t-loop; residues 366–406) that lies inside the kinase domain but outside the active-site cleft. the t-loop contains several residues that undergo autophosphorylation for efficient kinase activity (guo et al., 2010). finally, between residues 515 and 522, there is a nuclear localization signal that targets newly synthesized chk2 to this subcellular compartment (zannini et al., 2003).",pmc4296918,1,10,18,1,28
748,chk2,protein,,chek2,uniprot,o96017,nucleus,go:0005634,chk2 monomers,protein,monomer,chek2,uniprot,o96017,nucleus,go:0005634,positive,d,phosphorylation,sq/tq rich region,,,,,['31'],nan,nan,"chk2 activation and inactivation. (a) chk2 protein primary structure. (b) after dna damage, chk2 monomers are phosphorylated in the sq/tq rich region, dimerize, and become active upon autophosphorylation. successively they dissociate into active monomers. (c) chk2 inactivation is achieved by degradation, dephosphorylation, and inactivating phosphorylations.",pmc4296918,1,10,18,1,28
924,dp,protein,,,uniprot,q60496,plasma membrane,go:0005886,dp,protein,,,uniprot,q60496,plasma membrane,go:0005886,negative,d,phosphorylation,,transgenic mouse,heart,,mouse,['1701'],nan,nan,"to examine the role of dp ptms in vivo, we used a transgenic mouse model harboring full-length dp r2834h, which recapitulates features of the human disease ac. first, we investigated whether r2834h dp exhibits aberrant ptms in vivo by examining phosphorylation of flag-tagged dp in the mice. for this experiment, wt and r2834h dp transgenic hearts were lysed in urea sample buffer as performed previously and dp expression was assessed by immunoblot analysis (yang et al., 2006). total levels of dp expression were similar as shown by probing with anti-dp and anti-flag antibodies. phosphorylation of r2834h dp was dramatically decreased compared with wt dp using both the dp-specific phospho-antibody and a gsk3 substrate-specific phospho-antibody (r-x-x-ps; fig. 7, a and a′). tubulin was used as a loading control. these data support in vitro observations that r2834h dp decreases phosphorylation of dp compared with wt.",pmc4347645,1,10,18,1,28
2294,p21,protein,,,uniprot,p38936,nucleus,go:0005634,p21,protein,,,uniprot,p38936,nucleus,go:0005634,positive,d,phosphorylation,,,,,human,['1093'],nan,nan,"(a) hct116 k7as cells were stimulated (+) or not stimulated (−) with fetal bovine serum (fbs) for the indicated times in the absence (−) or presence (+) of 1-nmpp1. cell lysates were immunoprecipitated (ip) with anti-p21, anti-cyclin d1 (d1) or anti-cyclin d3 (d3) antibodies and separated by 2d gel electrophoresis followed by p21 immunodetection. (b) cho cells were transfected with a p21-expressing plasmid alone (left) or with plasmids encoding cyclin d3, cdk4-ha and p21 (right). cell lysates were immunoprecipitated (ip) with anti-p21 (p21) or anti-cyclin d3 (d3) antibodies and incubated with the indicated recombinant kinases and atp, before separation by 2d gel electrophoresis and p21 immunodetection. arrows indicate the main phosphorylated forms of p21 as identified in figure s4. (c) schematic representation and comparison of p21 patterns from hct116 k7as cells that were restimulated for 3 and 20 h (in vivo) and from cyclin d3-cdk4-p21 complexes produced in cho cells and phosphorylated by recombinant cdk2-cyclin e and cdk2-cyclin a (in vitro). the observed p21 forms are labeled according to their number of phosphorylations and the identified phosphorylated residues (e.g., 2p 98,130 means p21 phosphorylated at both s98 and s130; x, y, unidentified phosphorylated sites).",pmc3667761,1,10,18,1,28
3052,s6k1,protein,,rps6kb1,uniprot,o75582,,,p70s6k,protein,,rps6ka1,uniprot,p23443,,,positive,i,affecting,cell cycle,nsclc,lung cancer,,human,['3031'],nan,nan,"we hypothesized that by regulating the cell cycle, pf-4708671 may inhibit cell proliferation. recent studies showed that s6k1 and p70s6k are critical for g1 arrest [26–28]. consistently, we found that pf-4708671 affected cell cycle distribution in the three nsclc cell lines assessed, significantly delaying cell cycle progression in g0/g1 phase. another important factor affecting cell proliferation is apoptosis; a phase i trial of ly2584702 evaluating advanced solid tumor patients showed no overt anti-tumor effect by this drug [25]. as shown above, pf-4708671 had limited effect on cell apoptosis in nsclc cells, with an apoptosis rate close to 3% in vitro. therefore, we assumed that p70s6k pathways may not be involved in cell apoptosis. however, this study also demonstrated that pf-4708671 inhibits nsclc tumorigenesis in vivo.",pmc4714881,1,10,18,1,28
2427,p70s6k,protein,,,uniprot,p23443,cytoplasm,go:0005737,s6,protein,,,uniprot,p62753,cytoplasm,go:0005737,negative,d,phosphorylation,,,,,human,['3024'],nan,nan,"our results revealed that the specific p70s6k inhibitor pf-4708671 significantly reduced the phosphorylation of p70s6k and its downstream s6 at 0.1μm (p<0.05); p-s6 expression levels decreased with increasing drug concentrations (p<0.05). on the contrary, protein levels of downstream bad, caspase3 and erk were increased after treatment with pf-4708671 with the concentration of 1μm. however, total p70s6k and s6 protein levels had no significant differences between negative control and treatment groups (fig 1, s1 file).",pmc4714881,1,10,18,1,28
2652,pkc,protein,,,uniprot,,,,pkc,protein,,,uniprot,,,,positive,d,phosphorylation,carboxy-terminal residue,,,,human,['1182'],nan,nan,"analysis of the phosphorylation status of pkcs using the ppkc (pan) (βii s660) antibody which recognizes pkc α, βi, βii, δ, ε, η and θ phosphorylated at the carboxy-terminal residue homologous to s660 of pkc βii revealed that pkcs are considerably highly phosphorylated in pc3 than in pc3bm and hela (figure 2i).",pmc3010991,1,10,18,1,28
2774,pten,protein,,pten,uniprot,p60484,,,pten,protein,,pten,uniprot,p60484,,,negative,i,methylation,promoter,,breast cancer,breast,human,['1967'],nan,nan,"pten promoter methylation leads to low pten expression [349]. in one study, 26% of primary breast cancers had low pten levels that correlated with lymph node metastases and poor prognoses [350].",pmc3660063,1,10,18,1,28
2776,pten,protein,,pten,uniprot,p60484,nucleus,go:0005634,pten,protein,,pten,uniprot,p60484,centromere,go:0000779,negative,i,inhibition,centromere,,,breast cancer,human,['1964'],nan,nan,"germline pten mutations are present in approximately 80% of patients with cowden syndrome [328]. this disease, which is also known as multiple hamartoma syndrome, is a familial syndrome that includes diverse types of cancer conditions including early onset breast cancer. mutations have been reported to occur at pten in breast cancer in varying frequencies (5-21%) [329,330]. loss of heterozygosity (loh) is probably more common (30%) [330]. mutations at certain residues of pten, that are associated with cowden's disease, affect the ubiquitination of pten and prevent nuclear translocation. these mutations leave the phosphatase activity intact [331]. inhibition of pten activity leads to centromere breakage and chromosome instability [332]. thus pten has diverse activities.",pmc3660063,1,10,18,1,28
2886,ras,protein,gtpase,,,,cytosol,go:0005829,ras,protein,gtpase,,,,plasma membrane,go:0005886,negative,d,interacting,guanine nucleotide-free form of ras,,,,,['446'],nan,nan,"as a member of the small gtpase family, ras oscillates between an inactive gdp-bound state in the cytosol and an active gtp-bound form in the plasma membrane.32 recent studies suggest that pleckstrin homology domain leucine-rich repeat protein phosphatase (phlpp) has an important role in regulating ras activation by interacting with guanine nucleotide-free form of ras, hampering nucleotide binding for ras activation, thereby negatively modulating downstream erk pathway activation.32, 33 therefore, we checked the expression of phlpp in p27+/+ and p27−/−(δ51) cells. as shown in figure 6e, the basal level of phlpp was depleted in p27−/−(δ51) cells, and arsenite treatment decreased phlpp1 expression in p27+/+ cells. to verify whether the impaired expression of phlpp in p27−/−(δ51) cells led to increment in ras/erk/s6 pathway activation, we stably transfected ha-phlpp into p27−/−(δ51) cells, and the transfectants were identified by overexpression of ha and phlpp (figure 6f). the ectopic expression of ha-phlpp markedly reduced the activation of raf/mek/erk/p90rsk/s6 cascade (figure 6g). therefore, we concluded that phlpp expression was maintained by p27 and mediated the deactivation of ras/erk/s6 pathway in arsenite response.",pmc4260754,1,10,18,1,28
3041,s6k,protein,,,uniprot,o15590,cytoplasm,go:0005737,s6,protein,,,uniprot,p62753,cytoplasm,go:0005737,positive,d,phosphorylation,,,epithelial,,humans,['728'],nan,nan,"the contribution of unregulated s6k activity to tumorigenesis is currently unknown. some tsc1-2–deficient lesions have increased levels of phosphorylated s6, indicating elevation of s6k activity (kwiatkowski et al., 2002; karbowniczek et al., 2003). treatment of eker rat tumors, in which tsc2 is inactivated, with the mtor inhibitor rapamycin leads to increased apoptosis of these cells, indicating that mtor/s6k signaling may be important here (kenerson et al., 2002). however, it is also clear that mice rendered tsc-null by genetic means do not develop beyond mid-gestation (kwiatkowski et al., 2002), whereas in tsc, hamartomatous growths are generally slow or normally growing, and have a low malignant potential. this contrasts with pten inactivation in cowden disease, in which predisposition to malignancy is evident (starink et al., 1986). our model (fig. 8) suggests that an explanation for the low level of malignancy observed in tsc1-2–deficient tumors may be that insufficient pro-tumorigenic pip3-dependent signals (such as pkb activation) are generated in tsc1-2–deficient tumor cells, and that such signals may be required for malignant conversion. our data also suggest a paradigm of how appropriate organ size control may be achieved: cell growth through s6 kinases may be either coordinated with pi3k-regulated cell number control or uncoupled from it, depending on the presence or absence of a functional tsc1-2 complex.",pmc2172316,1,10,18,1,28
3451,v-src,protein,tyrosine kinase,src,uniprot,p12931,"cytoplasm, membrane","go:0005737, go:0016020",c-src,protein,tyrosine kinase,src,uniprot,p12931,"cytoplasm, membrane","go:0005737, go:0016020",positive,d,phosphorylation,tyrosine residues,,various,,"human, viral",['1387'],nan,nan,"protein-tyrosine phosphorylation was initially discovered as the catalytic property of the viral oncogene product v-src [1,2]. its cellular homologue, namely, the protein product of the c-src gene (src), also possesses the activity of a protein-tyrosine kinase (ptk). while the activity of v-src is deregulated (i.e., constitutively activated) and thus contributes to malignant cell transformation, the activity of the normal cellular src is usually negatively regulated and its signal-dependent transient activation contributes to physiological cell responses (e.g., proliferation, differentiation, cell motility) [3–5]. src is also recognized as the first example of a cytoplasmic as well as membrane-associated ptk, whose structural organization is shared by several other proteins, collectively termed the src family ptks [6]. src and other src family ptks are expressed ubiquitously (e.g., src, fyn and yes) or in certain specific tissues (e.g., lck in lymphoid cells), exerting both common and specific functions.",pmc3709701,1,10,18,1,28
